Catheter assembly including a multi-lumen configuration

Information

  • Patent Grant
  • 11918758
  • Patent Number
    11,918,758
  • Date Filed
    Monday, December 23, 2019
    4 years ago
  • Date Issued
    Tuesday, March 5, 2024
    a month ago
Abstract
A catheter assembly for use in accessing a vasculature of a patient is disclosed. In one embodiment, the catheter assembly includes a catheter body that includes a flattened oval outer surface and defines first and second lumens. The catheter body defines a distal tip region that includes a venous lateral opening that is in fluid communication with the first lumen and includes a distal-facing portion. The distal tip region further includes an arterial lateral opening that is in fluid communication with the second lumen, includes a distal-facing portion, and is substantially un-staggered with respect to the venous lateral opening. A distal end opening is in fluid communication with a power injectable third lumen. In another embodiment, the first and second lumens each generally include a reniform cross-sectional shape. In yet another embodiment, a dual-lumen catheter includes first and second lumens that each define a modified ellipse cross-sectional shape.
Description
BRIEF SUMMARY

Briefly summarized, embodiments of the present invention are directed to a catheter assembly for use in accessing a vasculature or other vessel of a patient during renal replacement or other suitable therapies. In one embodiment, the catheter assembly includes a catheter body that defines at least first and second lumens. The catheter body defines a distal tip region that includes at least one venous lateral opening that is in fluid communication with the first lumen and includes a distal-facing portion, and at least one arterial lateral opening that is in fluid communication with the second lumen and includes a distal-facing portion. The at least one arterial lateral opening is opposingly positioned in a substantially un-staggered configuration with respect to the at least one venous lateral opening. A distal end opening is defined on the distal tip region and is sized to pass a fluid therethrough. In one embodiment, the distal end opening is in fluid communication with a third lumen of the catheter body that can withstand high fluid flow rates associated with power injection of contrast media, for instance.


In another embodiment, a catheter assembly including a catheter body defining a first lumen and a second lumen is disclosed. The catheter body includes a distal tip region, which in turn includes a nose portion that defines a distally converging outer surface. A venous lateral opening, in fluid communication with the first lumen, is partially defined on the distally converging outer diameter. An arterial lateral opening, in fluid communication with the second lumen, is also partially defined on the distally converging outer diameter. The venous and arterial lateral openings are symmetrically disposed in a substantially un-staggered position with respect to one another. The distal tip portion further includes a distal end opening in fluid communication with one of the venous and arterial lumens and is sized to pass a guidewire therethrough.


In yet another embodiment, the first and second lumens each generally include a reniform cross sectional shape, while the third lumen is substantially round, interposed between the first and second lumens, and is power injectable.


These and other features of the present invention will become more fully apparent from the following description and appended claims, or may be learned by the practice of the invention as set forth hereinafter.





BRIEF DESCRIPTION OF THE DRAWINGS

To further clarify the above and other advantages and features of the present invention, a more particular description of the invention will be rendered by reference to specific embodiments thereof that are illustrated in the appended drawings. It is appreciated that these drawings depict only typical embodiments of the invention and are therefore not to be considered limiting of its scope. The invention will be described and explained with additional specificity and detail through the use of the accompanying drawings in which:



FIG. 1 is a perspective view of a catheter assembly incorporating various features of an embodiment of the present invention;



FIG. 1A is a perspective view of another example of a catheter assembly configured according to one embodiment;



FIG. 2 is a perspective view of a distal tip region of the catheter assembly shown in FIG. 1, configured according to one embodiment;



FIG. 3 is a side view of the catheter distal tip region of FIG. 2;



FIG. 4 is a top view of the catheter distal tip region of FIG. 2;



FIG. 5 is an end view of the catheter distal tip region of FIG. 2;



FIG. 6 is a perspective view of the catheter distal tip region of FIG. 2, depicting various details of lateral openings defined therein;



FIG. 7A is a cross sectional view of the catheter assembly and distal tip region of FIG. 2, showing the flow of blood therethrough in a “forward” flow configuration;



FIG. 7B is a cross sectional view of the catheter assembly and distal tip region of FIG. 2, showing the flow of blood therethrough in a “reverse” flow configuration;



FIG. 8A is a cross sectional view of the catheter assembly, taken along the line 8A-8A in FIG. 4;



FIG. 8B is another cross sectional view of the catheter tip, taken along the line 8B-8B in FIG. 4;



FIG. 8C is yet another cross sectional view of the catheter tip, taken along the line 8C-8C in FIG. 4;



FIG. 8D is yet another cross sectional view of a distal tip region of the catheter assembly showing positioning of a third lumen thereof in accordance with one embodiment;



FIGS. 9A-9F depict various views of a catheter assembly including a distal tip region configured in accordance with one embodiment;



FIGS. 10A-10D are perspective, front, side, and top views, respectively, of a catheter including a distal tip region configured in accordance with one embodiment;



FIGS. 11A-11D are perspective, front, side, and top views, respectively, of a catheter including a distal tip region configured in accordance with one embodiment;



FIGS. 12A-12D are perspective, front, side, and top views, respectively, of a catheter including a distal tip region configured in accordance with one embodiment;



FIGS. 13A-13D are perspective, front, side, and top views, respectively, of a catheter including a distal tip region configured in accordance with one embodiment;



FIGS. 14A-14D are perspective, front, side, and top views, respectively, of a catheter including a distal tip region configured in accordance with one embodiment;



FIGS. 15A-15D are perspective, front, side, and top views, respectively, of a catheter including a distal tip region configured in accordance with one embodiment;



FIGS. 16A-16D are perspective, front, side, and top views, respectively, of a catheter including a distal tip region configured in accordance with one embodiment;



FIGS. 17A-17D are perspective, front, side, and top views, respectively, of a catheter including a distal tip region configured in accordance with one embodiment;



FIGS. 18A-18D are perspective, front, side, and top views, respectively, of a catheter including a distal tip region configured in accordance with one embodiment;



FIGS. 19A-19D are perspective, front, side, and top views, respectively, of a catheter including a distal tip region configured in accordance with one embodiment;



FIGS. 20A-20D are perspective, front, side, and top views, respectively, of a catheter including a distal tip region configured in accordance with one embodiment;



FIG. 21 is a perspective view of a catheter assembly according to one embodiment;



FIGS. 22A and 22B are various perspective views of a distal portion of the catheter assembly of FIG. 21;



FIGS. 23A-23C are various cross-sectional views of the distal portion of the catheter assembly of FIG. 21;



FIG. 24 is a cross-sectional view of the catheter assembly of FIG. 21;



FIG. 25 is a cross-sectional view of a catheter assembly according to one embodiment;



FIG. 26 is a cross-sectional view of a catheter assembly according to one embodiment;



FIG. 27 is a perspective view of a catheter assembly according to one embodiment; and



FIG. 28 is a cross-sectional view of the catheter assembly of FIG. 27.





DETAILED DESCRIPTION OF SELECTED EMBODIMENTS

Reference will now be made to figures wherein like structures will be provided with like reference designations. It is understood that the drawings are diagrammatic and schematic representations of example embodiments, and are not limiting of the embodiments nor are they necessarily drawn to scale.


For clarity it is to be understood that the word “proximal” refers to a direction relatively closer to a clinician using the device to be described herein, while the word “distal” refers to a direction relatively further from the clinician. For example, the end of a catheter placed within the body of a patient is considered a distal end of the catheter, while the catheter end remaining outside the body is a proximal end of the catheter. Also, the words “including,” “has,” and “having,” as used herein, including the claims, shall have the same meaning as the word “comprising.”



FIGS. 1-20D depict various features of embodiments of the present invention, which are generally directed to an acute catheter assembly for use in accessing a vasculature or other vessel of a patient during renal replacement therapies such as hemodialysis or blood purification, though the principles of the present invention may be extended to other catheters employed in other uses in addition to these. Such acute catheters are typically employed in short-term placement scenarios such as a placement of less than 30 days, though the principles to be described herein can also apply to mid-term and long term catheter placements as well.


In accordance with one example embodiment, the catheter assembly includes a distal tip region defining separate venous and arterial lateral openings, in fluid communication with corresponding venous and arterial lumens that are employed for simultaneously infusing and aspirating blood from a vein or other vessel of a patient's vasculature during hemodialysis treatments. The venous and arterial lateral openings are disposed in a substantially equivalent, non-staggered position with respect to one another so as to enable positioning thereof in a predetermined region of the vasculature. This notwithstanding, the lateral openings are configured to reduce the likelihood of recirculation by the arterial segment of treated blood just returned to the vessel by the venous segment, thus increasing catheter efficiency. Moreover, the lateral openings can be operated in a reverse flow configuration without significantly impacting catheter efficiency during hemodialysis.


Embodiments of the catheter assembly to be described herein further include a distal end opening in fluid communication with a lumen of the catheter configured to withstand relatively high pressure and flow rates typically associated with power injection. This enables aspiration or infusion of fluids to occur via this lumen independently of the venous and arterial lumens. “Power injection” is defined herein to include fluid infusion under relatively high flow rates and/or relatively high pressures. For instance, in one embodiment power injection includes fluid infusion through a catheter lumen at a flow rate of between about three and about eight milliliters per second, and/or at a pressure of between about 50 and about 250 psi.


For clarity it is to be understood that the word “proximal” refers to a direction relatively closer to a clinician using the device to be described herein, while the word “distal” refers to a direction relatively further from the clinician. For example, the end of a catheter placed within the body of a patient is considered a distal end of the catheter, while the catheter end remaining outside the body is a proximal end of the catheter. Further, the words “including,” “has,” and “having,” as used herein, including the claims, shall have the same meaning as the word “comprising.”


Reference is first made to FIG. 1, which depicts various features of a hemodialysis catheter assembly, generally designated at 10, according to one example embodiment. As shown, the catheter 10 includes an elongate catheter body 11 including a proximal end 11A and a distal end 11B. The elongate catheter body 11 defines a first lumen 12, a second lumen 14, and a third lumen 15 (FIG. 7A) that longitudinally extend from the proximal end 11A to the distal end 11B thereof. The lumens 12, 14, and 15 can have one or more cross sectional shapes along their respective lengths, including round, oval, D-cross sectional shapes, or any combination thereof. In one embodiment, the first and second lumens 12, 14 are sized so as to accommodate fluid flow rates required for hemodialysis, i.e., about 300 milliliters/min. at about 250 millimeters Hg pressure. In one embodiment, the third lumen is sized with a diameter of about 0.035 to about 0.038 inch to accommodate blood draws and fluid aspiration/infusion therethrough.


A trifurcating hub 20 is included at the catheter body proximal end 11A, providing fluid communication between the first, second, and third lumens 12, 14, 15 and arterial extension leg 16, venous extension leg 18, and power extension leg 19, respectively. The extension legs 16, 18, 19 each include a luer connector 16A, 18A, 19A, and a clamp 16B, 18B, 19B. So configured, the extension legs 16, 18 provide fluid communication with the first and second lumens 12 and 14 so as to enable the infusion or aspiration of fluids from the central venous system of a patient. As such, fluid infusion or aspiration devices, such as a hemodialysis apparatus for example, may be connected to the catheter assembly 10 via the luer connectors 16A, 18A, thus providing intravascular access to the patient. Similarly, the extension leg 19 provides fluid communication with the third lumen 15 to enable fluid infusion/aspiration from the vein when a corresponding device is connected thereto via the connector 19A. Note that the respective positions and configurations of the extension legs detailed here can change according to a particular catheter assembly design and therefore not be viewed as limiting. The catheter body 11 further includes a suture wing 21 for providing securement of the catheter body to the patient.



FIG. 2 shows the catheter assembly 10 according to another example embodiment, wherein the extension legs 16, 18 each include a pre-curved portion 16C, 18C. The pre-curved portions 16C, 18C enable the extension legs 16, 18 of the catheter assembly 10 to extend downward against the patient's body once the distal portion of the catheter assembly has been placed in the vasculature to provide patient comfort.


In greater detail, the power extension leg 19 of FIGS. 1 and 2 fluidly connects to the third lumen 15 via the trifurcating hub 20. In particular, the power extension leg 19 is configured in one embodiment to enable rapid infusion, i.e., power injection, of contrast media, useful for contrast-enhanced CT scan imaging, or other fluids into the patient vessel via the third lumen 15. Specifically, in one embodiment, the power extension leg 19 and third lumen 15 are configured to infuse fluids at a rate of between about 3 milliliters and about 8 milliliters per second and at a fluid pressure of between about 50 and 250 psi, though other flow rates and fluid pressures may also be possible. The power extension leg 19 and third lumen 15 can also be used to remove blood or other fluids alone or during simultaneous use of the first and second lumens 12 and 14, and to monitor central venous pressure with the assistance of a transducer. The power extension leg 19 and third lumen 15 are also sufficiently sized to receive a guidewire therethrough to enable insertion of the catheter assembly over the guidewire. Note that the components of the power extension leg 19 are colored purple in one embodiment to indicate power injectability. Other colors could also be used.


Both FIGS. 1 and 2 further include a distal tip region, generally designated at 50, that is configured in accordance one example embodiment of the present invention, the details of which are given below. It should be appreciated that the distal tip region to be described below can be included with hemodialysis catheters, such as those shown in FIGS. 1 and 2, or with other catheters, such as central venous catheters, for example. Indeed, the catheter assembly according to embodiments of the present invention can be adapted for use in other applications, such as chronic dialysis treatment, or where access is desired to be gained to a vessel, such as the internal jugular, subclavian, or femoral vessels, or other body lumen of a patient. Examples of such other applications include apheresis, hemoperfusion, etc.


Reference is now made to FIGS. 2-6, which show various views of a distal tip region, generally designated at 50, of the catheter assembly 10 and configured according to one example embodiment. In detail, the distal tip region 50 generally includes a terminal catheter portion 50A and a nose portion 50B disposed distally of the terminal catheter portion to define a distal end of the catheter assembly 10. The terminal catheter portion 50A, as part of the more proximal portion of the catheter body 11, is composed of suitable material(s) that exhibit qualities, such as suitable softness to allow for ease of insertion without causing vessel trauma, and biocompatibility for enabling the catheter to operate as intended. In one embodiment, the catheter body 11 is composed of material(s) including a thermoplastic polyurethane-based resin material, specifically a polyether-based, aliphatic thermoplastic polyurethane sold under the trademark TECOFLEX, namely TECOFLEX EG-60D-B20, having a Shore D hardness of approximately 60, where “B20” refers to the radiopacifier loading, i.e., barium sulfate loading at 20%. Other suitable materials can also be employed.


In contrast, the nose portion 50B includes a material relatively softer than that of the terminal catheter portion 50A so as to prevent the tip portion from damaging the vessel or other vasculature during vessel entry or transit. In one embodiment, the nose portion 50B is composed of material(s) including TECOFLEX EG-85A-B20 having a Shore A hardness of approximately 85. Notwithstanding the above description, it should be appreciated that the terminal catheter portion and the nose portion can include other materials having the desired properties as described herein and as appreciated by one skilled in the art. One non-limiting example of material that can be used for the terminal catheter portion and nose portion is silicone.


Note that in the illustrated embodiment, the nose portion 50B is joined to the terminal catheter portion 50A via a molding process during manufacture of the catheter assembly 10. In other embodiments, however, other processes for joining the nose portion to the catheter body can be employed, including for instance RF fusion (RF tipping), bonding via adhesive, integrally forming the nose portion with the catheter body, etc.


As best seen in FIGS. 3 and 4, the nose portion 50B is distally converging. In the present embodiment, the nose portion 50B is tapered so as to ease entry and passage of a distal portion of the catheter body 11 into the vasculature or other internal cavity of a patient. The nose portion 50B may be colored differently from the remainder of the catheter body 11 to indicate that the catheter assembly 10 can be employed for relatively rapid fluid aspiration and infusion via the third lumen 15 and corresponding power extension leg 19, as was described further above.


The distal tip region 50 includes various openings for enabling the infusion and aspiration of fluids while the catheter assembly 10 is placed for use within the patient vasculature. Specifically, and in accordance with one embodiment, the distal tip region includes a venous lateral opening 60, an arterial lateral opening 62, and a distal end opening 64.


In greater detail, the venous and arterial lateral openings 60 and 62 are positioned opposite one another proximate the catheter body distal end 11B and are defined in a lateral portion of an outer wall of the catheter body 11 so as to be in fluid communication with first lumen 12 and the second lumen 14, respectively, thus enabling blood or other fluids to flow via the openings to/from the lumens when the catheter assembly 10 is positioned within the patient's vasculature. The venous and arterial lateral openings 60 and 62 are defined by perimeters 60A and 62A, respectively, as best seen in FIG. 4 and described further below.


Note that each of the lateral openings 60 and 62 distally extends from the terminal catheter portion 50A into the nose portion 50B. Of course, the exact placement of the lateral openings 60 and 62 along the longitudinal length of the catheter body 11 can vary according the needs of a particular application.



FIG. 4 shows that in the present embodiment the venous and arterial lateral openings 60 and 62 are substantially un-staggered, i.e., equally placed with respect to one another along the longitudinal length of the catheter body 11 such that each is substantially disposed an equal distance from the distal catheter end 11B. Such un-staggered disposal of the lateral openings 60 and 62 enables both openings to be placed proximate a desired location within the vasculature and ensures that the recirculation rate of already treated blood through the catheter assembly 10 is held relatively constant regardless the respective directions of blood travel in/out of the lateral openings. This feature is useful should reversal of blood flow directions through the catheter be necessary. In one embodiment, the recirculation rate in either direction is less than or equal to about five percent. In another embodiment, the venous and lateral openings can be staggered.



FIGS. 2-6 further show the manner in which the venous and lateral openings 60 and 62 are defined in the distal tip region 50. The lateral openings 60 and 62 can take various shapes and configurations as will be shown further below, but in the present embodiment the lateral openings are defined by angled cross-drilled cuts through the outer wall of the catheter body 11 to establish communication with the respective first or second lumens 12, 14. In one embodiment, such cuts are referred to as “skive” cuts.


In one embodiment, a long axis of each cross-drilled cut of the lateral openings 60, 62 defines in one embodiment an angle θ1 of about 35 degrees with a longitudinal axis of the catheter body 11, though this angle can vary in one embodiment from about greater than zero to about 90 degrees. This angular character imparts both a lateral and distal directional component to fluid flow out of either lateral opening 60, 62, as represented by the flow arrows in FIG. 4, which assists in enabling low-recirculation fluid flow out of or into either lateral opening. Each lateral opening 60 and 62 in the present embodiment is defined by identical cross cuts having the same angle θ1 with respect to the longitudinal axis 70, though it is also possible to vary the angle generally, or to vary the angle differently for each opening.


In one embodiment, the lateral openings can be defined by a compound-angle cross cut, wherein the long axis of each lateral opening defines an angle with the catheter body longitudinal axis and with a plane dividing the first lumen and the second lumen, i.e., coplanar with the septum separating the first and second lumens proximal of the distal tip region.


An end view of the cross cut, depicted in FIG. 6, shows that the cross cut of each opening 60 and 62 in the illustrated embodiment is made so as to generally define a semicircular cavity through a peripheral portion of the distal tip region 50. This cavity is defined by a portion of a circle 72 having a radius “R,” shown in FIG. 6. In the present embodiment, the cross cut that defines the lateral openings 60 or 62 is achieved via use of a cylindrical drill bit or coring tool having a radius equal to the radius R of the circle 72 and cutting through the distal tip region 50 set at the angle θ1. For instance, in one embodiment a drill bit having a radius of 1/16 inch is used to diagonally cross cut the venous and arterial lateral openings 60 and 62 through a catheter body defining an oblong cross section, wherein the average of the major and minor diameters is approximately 0.173 inches. Note that the catheter body size in one embodiment can vary from 7-16 Fr., though other French sizes are also possible. Though shown in connection with the venous lateral opening 60, the above description applies to the arterial opening 62 as well. Note here that, though identically sized and shaped in the present embodiment, the first and second openings could have respectively differing dimensions if desired or needed for a particular application.


As a result of defining the cross cuts as just described, the venous and arterial openings 60 and 62 are defined by their respective perimeters 60A and 62A discussed above. The angle at which the cross cuts are made, together with the shape of the catheter body 11 at the point of the cuts, results in the perimeters 60A and 62A shaped as seen in the accompanying figures. As best seen in FIG. 4, each perimeter 60A and 62A defines in the present embodiment a figure-eight shape, or analemma, when viewed in a two-dimensional perspective and an elongate saddle shape when viewed in a three-dimensional perspective. Further, because a distal portion of each opening 60 and 62 is defined on a portion of the tapered nose portion 50B (best seen in FIGS. 4 and 5), each opening has a distal-facing component, best seen in FIG. 5, wherein a portion each lateral opening is distally visible.


The configuration of the venous and arterial lateral openings 60 and 62 described above provides various aspects for the catheter assembly 10. First, because of their saddle shapes, the lateral openings 60 and 62 partially extend circumferentially about the outer perimeter of the catheter body 11. This helps to prevent undesired suctioning of the distal tip region 50 to the vessel wall when one of the openings is removing blood from the vessel as the negative flow pressure of the opening is distributed about a portion of the catheter body circumference. If vessel suck-up does occur, the lateral openings 60, 62 are shaped so as to nonetheless provide acceptable fluid flow in and out of the catheter assembly 10. The relatively large size of the lateral openings 60 and 62 also assists in the prevention of occlusion or sheath formation and provides a fanned-out or wide distribution of fluid flowing out therefrom. Recirculation efficiency rates are improved as a result.


Second, the distal-facing aspect of each lateral opening 60 and 62 assists in imparting a distal direction to fluids being ejected therefrom. This enables the ejected fluid to distally flow away from one respective lateral opening and distal-to proximal flow into the other lateral opening even when the catheter body 11 is positioned against a vessel wall. In addition, the lateral openings 60, 62 are symmetrically opposed, in direction from one another, i.e., a 180-degree separation as best shown in FIG. 4, so as to ensure fluid entry and exit from the lateral openings occurs on opposite sides of catheter assembly 10, further reducing recirculation. Furthermore, this symmetric positioning produces a “criss-cross” relationship between the lateral openings 60 and 62, as best seen in FIG. 3, which assists in reducing recirculation. Moreover, similar fluid flow characteristics are realized even when fluid flow through the catheter assembly 10 is reversed, as discussed further below. In addition, the lateral opening configuration described herein minimizes radical redirection of the fluid upon exiting the catheter body 11 via either of the lateral openings 60 or 62, which in turn prevents fluid turbulence and possible clotting or hemolysis.


As shown in FIGS. 2-6, the distal end opening 64 is distally located at the distal end of the distal tip region nose portion 50 and is in fluid communication with the third lumen 15 so as to enable high flow rate infusion, i.e., power injection of contrast media or other fluids such as TPN nutritional fluid and medications into the vessel, as well as the removal of blood from the vessel during catheter use. In the case of infusion of contrast media or medications into the vessel, placement of the distal end opening 64 distally of the first and second openings 60 and 62 advantageously results in minimization of contrast media/medication intake into either of the first or second openings if the infusion takes place simultaneously with fluid passage through the venous and arterial openings 60 and 62, such as during hemodialysis or other treatments.


Note that, in one embodiment a guidewire can be inserted through the distal end opening 64, the third lumen 15, and the power extension leg 19 during initial or exchange catheter placement in the patient vasculature. Also note that the relatively proximate placement of the three openings 60, 62, and 64 in the distal portion of the catheter body 11 enables each opening to be placed near desired location within the vasculature, such as the superior vena cava (“SVC”).


Reference is now made to FIGS. 7A and 7B in describing flow characteristics with respect to the configuration of the distal tip region 50 of the catheter assembly 10 according to the present embodiment. FIGS. 7A and 7B show the distal tip region 50 after the catheter assembly 10 has properly positioned within a vessel of a patient. Arrow 84 shows the direction of blood flow past the distal tip region 50 within the patient's vessel.


In greater detail, FIG. 7A shows fluid flow through the distal tip region 50 in a “forward” direction, wherein blood is aspirated by the second lumen 14, or “uptake” lumen, for removal from the body and treatment by a hemodialysis apparatus or for some other suitable purpose. Aspirated blood enters the second lumen 14 via the arterial lateral opening 62 of the distal tip region 50. Similarly, blood is infused, or returned, to the vessel by the first lumen 12, or “return” lumen, after treatment by a hemodialysis apparatus or some other suitable purpose. Infused blood exits the first lumen 12 from the venous lateral opening 60. Note that the lateral orientation of the venous and arterial lateral openings 60, 62 provides for low recirculation of already-treated blood within the vessel, recirculation being defined as already-treated blood that is returned to the bloodstream via the venous lumen being immediately aspirated by the arterial lumen to be re-treated. Such recirculation is undesirable as it results in lower treatment efficiency, resulting in longer treatment time.


During hemodialysis procedures, it is sometimes necessary to reverse the blood flow through the catheter assembly 10. FIG. 7B shows fluid flow through the distal tip region 50 during such a “reverse” flow situation. In contrast to the forward flow conditions of FIG. 7A, the second lumen 14 in FIG. 7B is employed to infuse blood into the vessel while the first lumen 12 aspirates blood from the vessel. In this configuration, the infused blood enters the vessel via the arterial lateral opening 62, while the aspirated blood is removed via the venous lateral opening 60. Again, the lateral orientation of the venous and arterial lateral openings 60, 62 provides for low recirculation of already-treated blood within the vessel. Thus, it is seen that low recirculation results regardless of the direction in which the catheter is operating.



FIGS. 7A and 7B further show that fluid can be aspirated or infused via the distal end opening 64 in fluid communication with the third lumen 15 before, after, or during infusion/aspiration by the venous and arterial lateral openings 60, 62. As mentioned, the third lumen 15 and distal end opening 64 are configured so as to withstand relatively high pressurized fluid flow infusion into the vessel. It is appreciated that in other embodiments, more than one of the catheter lumens can be configured for high pressurized fluid flow infusion, if desired.


It should be appreciated that the labels “venous” and “arterial” as used above in describing the various components of the present catheter assembly are employed for sake of convenience in describing aspects of present embodiments. Indeed and as just described, though the arterial lateral opening is normally employed in hemodialysis procedures for aspirating blood from the blood vessel in which the catheter is disposed and the venous lateral opening for returning already treated blood to the vessel, this can be reversed such that blood is returned via the arterial lateral opening and aspirated by the venous lateral opening. As such, embodiments of the present invention should not be considered limited by the use of this and other descriptive terminology herein.


Reference is now made to FIGS. 8A-8C, which depict various details regarding the catheter body 11. In detail, FIG. 8A shows a cross sectional view of the catheter body 11 at a point proximal to the distal tip region 50, showing the first lumen 12, the second lumen 14, and the third lumen 15. The three lumens 12, 14, 15 are defined along the longitudinal length of the catheter body 11 and bounded by an outer perimeter or wall 86. The outer wall 86 of the catheter body 11 in the present embodiment defines an oblong shape and includes a transverse axis 88 that intersects the first and second lumens 12, 14 and spans the width of the catheter body. Placement of the first and second lumens 12, 14 adjacent one another, with the third lumen 15 positioned therebelow, provides a robust lumen configuration that resists inadvertent closure of lumens via kinking of the catheter body 11. In addition, the oblong cross sectional configuration of the catheter body 11 enables circular cross sectional shapes to be employed for the lumens 12, 14, and 15, which are relatively more efficient than “D”-shaped or other shaped lumens in terms of fluid flow.


As seen in FIG. 8B and as previously described, the venous lateral opening 60 is defined so that it intercepts the first lumen 12, while the arterial lateral opening is defined so that it intercepts the second lumen 14. As such, the first lumen 12 establishes fluid communication between the venous extension leg 18 and the venous lateral opening 60, while the second lumen 14 establishes fluid communication between the arterial extension leg 16 and the arterial lateral opening 62. In one embodiment, the angled cross cuts that define the venous and arterial openings 60 and 62 are made tangentially with respect to a septum 90 separating the first and second lumens 12, 14 such that the septum wall remains intact as a barrier between the two lumens.



FIGS. 8A-8C successively depict the manner in which the third lumen is raised from a bottom-central location along the length of the catheter body 11 to a central position upon its exit at the distal end opening 64, as shown in FIG. 5. Of course, other lumen position configurations are also possible.


It is appreciated that various modifications may be made to the catheter assembly configurations described above. It is noted that for purposes of clarity, only selected differences between the foregoing and following embodiments are described. For instance, FIGS. 9A-9F depict a distal tip region 150 including a terminal catheter portion 150A integrally formed with the catheter body 11 and a nose portion 150B including a relatively low hardness, e.g., soft, material and joined to the terminal catheter portion 150A in a manner similar to that already described above in connection with FIGS. 2-6.


The distal tip region 150 defines a venous lateral opening 160 in fluid communication with the first lumen 12 and an arterial lateral opening 162 in fluid communication with the second lumen 14. A distal end opening 164 is also defined at a distal end of the nose portion 150B. The catheter assembly as configured in FIGS. 9A-9F is a dual lumen device in that it includes only two lumens 12 and 14 (FIG. 9E). As best seen in FIG. 9F, therefore, the distal end opening 164 does not communicate with a third lumen, but rather with a guidewire channel 164A defined by the nose portion 150B, which in turn communicates with the first lumen 12. In this way, a guidewire pathway is established through the catheter body 11 and distal tip region 150 to enable the catheter assembly to be inserted over a guidewire during initial placement and catheter exchange procedures.



FIG. 9E depicts a cross sectional view of the catheter body proximal of the distal tip region 150. As shown, top and bottom portions of an outer wall 186 of the catheter body 11 include thickened regions 186A, which provide added kink resistance to the catheter body.


By virtue of its communication with the first lumen 12, the guidewire channel 164A provides an added fluid outlet/inlet for the first lumen via the distal end opening 164, thus providing an additional fluid pathway that further reduces recirculation during operation of the catheter. This fluid communication also maintains the guidewire channel 164A patent via the flow of blood therethrough so as to prevent occlusion thereof. Further note that, though it is centrally located at the distal end of the nose portion 150B, the venous lateral opening 164 can be positioned such that it and the corresponding guidewire channel 164A are in longitudinal linear alignment with the first lumen 12. Further, the venous lateral opening and the corresponding guidewire channel can be configured as to be in communication with the second lumen or both the first and second lumens, if desired.



FIGS. 10A-10D and 11A-11D are further examples of a dual lumen catheter assembly configuration, in accordance with example embodiments thereof. The distal tip regions 250/350 each include a terminal catheter portion 250A/350A and a nose portion 250B/350B at which are defined a venous lateral opening 260/360, an arterial lateral opening 262/362, and a distal end opening 264/364. A guidewire channel 264A/364A is defined between the distal end opening 264/364 to the first lumen 12 so as to be in communication therewith. As can be seen in comparison, the lateral openings 260, 262 of FIGS. 10A-10D are differently shaped from corresponding lateral openings 360, 362 of FIGS. 11A-11D. Further, the nose portion 250B (FIG. 10A) is distally converging in a tapered configuration, whereas the nose portion 350B (FIG. 11A) distally converges in a rounded configuration to define a bullet-shape. Note also that the venous and arterial lateral openings of the dual lumen embodiments describe herein include distal-facing portions, as best seen in FIGS. 10B and 11B, offering characteristics similar to those outlined above in connection with the discussion relating to FIGS. 2-6.



FIGS. 12A-20D depict possible configurations of a catheter assembly distal tip region including three lumens, according to additional example embodiments. As they share aspects with the embodiment described above in connection with FIGS. 2-7B, only selected aspects of the embodiments to follow will be discussed below.



FIGS. 12A-12D depicts a catheter assembly distal tip region 450, including a terminal catheter portion 450A and a nose portion 450B. The distal tip region 450 further includes a venous lateral opening 460 in fluid communication with the first lumen 12 and an arterial lateral opening 462 in fluid communication with the second lumen 14. A distal end opening 464 is also defined at a distal end of the nose portion 450B. In the present embodiment, the lateral openings 460 and 462 each define a trapezoidal perimeter when viewed from the perspective of FIG. 12D, and are symmetrically opposed from one another.



FIGS. 13A-13D depicts a catheter assembly distal tip region 550, including a terminal catheter portion 550A and a nose portion 550B. The distal tip region 550 further includes a venous lateral opening 560 in fluid communication with the first lumen 12 and an arterial lateral opening 562 in fluid communication with the second lumen 14. A distal end opening 564 is also defined at a distal end of the nose portion 550B. In the present embodiment, the lateral openings 460 and 462 each define a stepped perimeter when viewed from the perspective of FIG. 13D, and are symmetrically opposed from one another.



FIGS. 14A-14D depict a catheter assembly distal tip region 650, including a terminal catheter portion 650A and a nose portion 650B. The distal tip region 650 further includes a venous lateral opening 660 in fluid communication with the first lumen 12 and an arterial lateral opening 662 in fluid communication with the second lumen 14. A distal end opening 664 is also defined at a distal end of the nose portion 650B and is axially offset from a central axis of the catheter body 11. In the present embodiment, the lateral openings 660 and 662 each define an oval perimeter when viewed from the perspective of FIG. 12C, and are symmetrically opposed from one another, as best seen in FIG. 14D.



FIGS. 15A-15D depict a catheter assembly distal tip region 750, including a terminal catheter portion 750A and a nose portion 750B. The distal tip region 750 further includes a venous lateral opening 760 in fluid communication with the first lumen 12 and an arterial lateral opening 762 in fluid communication with the second lumen 14. A distal end opening 764 is also defined at a distal end of the nose portion 750B and is axially offset from a central axis of the catheter body 11. In the present embodiment, the lateral openings 760 and 762 each define an oval perimeter when viewed from the perspective of FIG. 15C, and are symmetrically opposed from one another, as best seen in FIG. 15D.



FIGS. 16A-16D depict a catheter assembly distal tip region 850, including a venous lateral opening 860 in fluid communication with the first lumen 12 and an arterial lateral opening 862 in fluid communication with the second lumen 14. A distal end opening 864 is also defined at a distal end of the distal tip region 850 and is axially offset from a central axis of the catheter body 11. In the present embodiment, the lateral openings 860 and 862 are separated by a septum 890, and each defines a partial oval perimeter when viewed from the perspective of FIG. 16C, and are symmetrically opposed from one another, as best seen in FIG. 16D.



FIGS. 17A-17D depict a catheter assembly distal tip region 950, including a venous lateral opening 960 in fluid communication with the first lumen 12 and an arterial lateral opening 962 in fluid communication with the second lumen 14. A distal end opening 964 is also defined at a distal end of the distal tip region 850 and is axially offset from a central axis of the catheter body 11. In the present embodiment, the lateral openings 960 and 962 are separated by a septum 990, and each defines an acute angle-shaped perimeter together with a portion of an outer catheter body wall 986 when viewed from the perspective of FIG. 16C. As before, the lateral openings 960, 962 are symmetrically opposed from one another, as best seen in FIG. 17D.



FIGS. 18A-18D depict a catheter assembly distal tip region 1050, including a terminal catheter portion 1050A and a nose portion 1050B. The distal tip region 1050 further includes a venous lateral opening 1060 in fluid communication with the first lumen 12 and an arterial lateral opening 1062 in fluid communication with the second lumen 14. A distal end opening 1064 is also defined at a distal end of the distal tip region nose portion 1050B and is centrally disposed with respect to a central axis of the catheter body 11. In the present embodiment, the lateral openings 1060 and 1062 are separated by a septum 1090, and each defines a partial oval perimeter when viewed from the perspective of FIG. 18C. As before, the lateral openings 1060, 1062 are symmetrically opposed from one another, as best seen in FIG. 18D.



FIGS. 19A-19D depicts a catheter assembly distal tip region 1150, including a nose portion 1150B. The distal tip region 1150 further includes a venous lateral opening 1160 in fluid communication with the first lumen 12 and an arterial lateral opening 1162 in fluid communication with the second lumen 14. A distal end opening 1164 is also defined at a distal end of the distal tip region 1150 and is axially offset from a central axis of the catheter body 11. In the present embodiment, the lateral openings 1160 and 1162 each define a triangular perimeter when viewed from the perspective of FIG. 19D, and are symmetrically opposed from one another as best seen in FIG. 19D.



FIGS. 20A-20D depict a catheter assembly distal tip region 1250, including a terminal catheter portion 1250A and a nose portion 1250B. The distal tip region 1250 further includes a venous lateral opening 1260 in fluid communication with the first lumen 12 and an arterial lateral opening 1262 in fluid communication with the second lumen 14. A distal opening 1264 is also defined on the nose portion 1250B and is axially offset from a central axis of the catheter body 11. In the present embodiment, the lateral openings 1260 and 1262 are separated by a septum 1290, and each defines a frustoconical perimeter when viewed from the perspective of FIG. 20C. As before, the lateral openings 1260, 1262 are symmetrically opposed from one another, as best seen in FIG. 20D. In addition to the lateral openings 1260, 1262, the terminal catheter portion 1250A further includes a plurality of venous openings 1260A and a plurality of arterial openings 1262A. The openings 1260A, 1262A are relatively smaller than the lateral openings 1260, 1262, and are distributed about the perimeter of the catheter body so as to further reduce the possibility of vessel wall suck-up.



FIGS. 21-24 depict various details of a catheter assembly 1310 according to one embodiment. Note that the embodiments described below include various similarities to the embodiments described above; as such, only selected aspects will be discussed below.


As shown, the catheter assembly 1310 includes an elongate catheter tube, or catheter body 1311, which defines a plurality of lumens extending from a proximal end 1311A to a distal end 1311B. The proximal end 1311A of the catheter body 1311 is operably attached to a bifurcation 1320, which in turn is operably attached to extension legs, namely an arterial extension leg 1316, a venous extension leg 1318, and a power extension leg 1319 suitable for power injection of a fluid therethrough. The number of catheter body lumens, extension legs, and their respective configurations can vary from what is shown and described herein. For instance, though shown in FIG. 21 as straight, the arterial and venous extension legs 1316, 1318 can each be curved in a U-shaped configuration, in one embodiment. These and other modifications are contemplated. Note also that “bifurcation” is understood to include a hub that provide two or more fluid pathways.


With continuing reference to FIG. 21, reference is made to FIGS. 22A and 22B, which depict distal portions of the catheter assembly 1310 and its elongate catheter body tube 1311, according to the present embodiment. As shown, the distal portion of the catheter body 1311 includes features similar to those shown in FIGS. 1-5 (discussed further above), including a tapered distal tip region 1350, in contrast to the cylindrically flattened oval-shaped outer surface of the more proximal portion of the catheter body, a venous lateral opening 1360, and an arterial lateral opening 1362. The arterial and venous and arterial lateral openings 1360 and 1362 are in fluid communication with respective arterial and venous lumens, which are referenced below and defined by the catheter body 1311. Each of the venous and arterial lateral openings 1360 and 1362 is defined by an angled skive cut so as to impart an angular direction component, with respect to the longitudinal axis of the catheter tube 1311, to fluid entering (via the arterial distal opening) or exiting (via the venous distal opening) the catheter tube, as before.


A third lumen distal end opening 1364 is included at the distal end of the distal tip region 1350 and is in fluid communication with a third lumen defined by the catheter body 1311, as discussed below. In addition, side holes 1342 are included in the catheter body 1311 proximal to the distal tip region 1350, which are in fluid communication with one of the arterial and venous lumens. Such side holes provide an alternate fluid path in addition to the venous and arterial lateral openings 1360, 1362. Note that the particular configuration of the various lateral and side hole openings can vary from what is shown and described herein.



FIGS. 23A-23C depict the lumen configuration of the catheter body 1311 according to the present embodiment. As shown, an outer perimeter, or outer wall 1386 having a substantially flattened oval cross-sectional configuration defines the external portion of the catheter 1311. Indeed, the outer wall 1386 bounds a first, arterial lumen 1312, a second, venous lumen 1314, and a third lumen 1315, as mentioned above. A septum 1390 cooperates with the outer wall 1386 to define the particular shape configurations of the three lumens 1312, 1314, and 1315, which each substantially extend the longitudinal length of the catheter body 1311. FIG. 23B shows the manner in which the arterial lumen 1312 and venous lumen 1314 communicate with the arterial lateral opening 1362 and the venous lateral opening 1360, while FIG. 23C shows the manner in which the third lumen 1315 extends distally toward the distal end opening 1364 on the distal tip region 1350.



FIG. 24 depicts further details regarding the cross-sectional lumen configuration of the catheter body 1311, according to the present embodiment. As shown, the flattened oval outer wall 1386 and the septum 1390 of the catheter body 1311 define the arterial lumen 1312, the venous lumen 1314, and the third lumen 1315, as mentioned above. FIG. 24 shows that the third lumen 1315 has a cross-sectional shape that is substantially round and is configured in one embodiment to withstand fluid pressures typically associated with power injection, e.g., about 300 psi in one example.


The cross-sectional configurations of the arterial and venous lumens 1312, 1314 are mirror projections of each other as taken across the center line (“CL”) indicated at 1389 in FIG. 24. In particular, both the arterial and venous lumens 1312, 1314 cross-sectionally define a deformed kidney bean-shaped cross-sectional lumen profile, also referred to herein as a modified reniform shape. In greater detail, each of the arterial and venous lumens 1312, 1314 cross-sectionally defines a concavely-shaped portion, or concavity 1394, which contributes to the reniform lumen shape. The concavity 1394 for each lumen 1312, 1314 is disposed above a transverse axis 1388 of the catheter body 1311 as shown in and from the perspective of FIG. 24. Disposal of the concavity 1394 of each lumen 1312, 1314 above the transverse axis 1388, as opposed to the concavity being centered on the transverse axis results in a modified reniform configuration, though it is appreciated that the size and location of the concavity can vary from what is shown and described herein. Indeed, in one embodiment the concavity can be positioned so as to define a general reniform (un-deformed kidney bean) shape.


Each lumen 1312, 1314 further includes an arcuate portion, or major arc 1398, opposite the respective concavity 1394 that defines an outer portion of each lumen adjacent the outer wall 1386. The major arc 1398 of each lumen 1312, 1314 is bounded on either end by a top corner 1396A and a bottom corner 1396B. This configuration interposes the top corner 1396A between the major arc 1398 and the concavity 1394. The top and bottom corners 1396A and 1396B are substantially rounded to ensure a laminar flow of fluids through the arterial and venous lumens 1312, 1314, thus desirably preventing areas of fluid flow stagnation.


As shown in FIG. 24, the septum 1390 is included to separate the arterial lumen, 1312, the venous lumen 1314, and the third lumen 1315. Centered on the center line 1389, the septum 1390 includes a unified portion 1390A that generally extends downward from the transverse axis 1388 (from the perspective shown in FIG. 24) and a bifurcated portion 1390B that generally extends upward from the transverse axis. Particularly, the septum 1390 helps define the aformentioned shapes of the lumens. For example, the unified portion 1390A of the septum 1390 generally defines an hourglass-like cross-sectional shape to help define the rounded bottom corners 1396B and the inner portions of both the arterial lumen 1312 and venous lumen 1314, while the bifurcated portion 1390B of the septum cooperates with the outer wall 1386 to define the cross-sectional shape of the third lumen 1315 and the concavities 1394 of the arterial and venous lumens. Note also that the general hourglass configuration of the septum 1390 adds structural strength to the septum.


The cross-sectional configuration shown in FIG. 24 in the present embodiment extends from the proximal end 1311A of the catheter body 1311 distally to the arterial and venous lateral openings 1362, 1360, though this can be modified in other embodiments. It is noted that the various cross-sectional features of the catheter body 1311 described immediately above can vary in size, shape, and position from what is shown and described herein.


According to one embodiment, the various features described above include the following cross-sectional dimensions: the perimeter of the outer wall 1386 includes a width of about 0.195 inch and a height of about 0.128 inch; the diameter of the third lumen is about 0.040 inch; the thickness of the unified portion 1390A of the septum 1390 is about 0.015 inch; the thickness of each branch of the bifurcated portion 1390B of the septum 1390 at the midpoint of the respective concavity 1394 is about 0.010 inch; the distance between the outer surface of the outer wall and the nearest point of the third lumen is about 0.010 inch; the thickness of the outer wall at about the midpoint of the major arc 1398 is about 0.015 inch; the radius of each concavity of the identical arterial and venous lumens 1312, 1314 as measured from a center point of the third lumen is about 0.030 inch; the radius of each top corner 1396A is about 0.012 inch; the radius of each bottom corner 1396B is about 0.020 inch; the radius of each major arc is about 0.052 inch; the radius at the end of the concavity opposite the top corner (at about the transverse axis 1388) is about 0.030 inch; and the distance between the outer surface of the outer wall and the nearest point of arterial or venous lumen proximate the bottom corner thereof is about 0.010 inch. Note that the lumen configuration of the present embodiment enables fluid flow therethrough equal to a known 13 French-sized catheter while occupying the size of only a 12 French catheter. Of course, the size of the catheter body and its respective lumens can be scaled as needed/desired.


The catheter body 1311 in one embodiment includes a suitable thermoplastic such as polyurethane, for instance. In some embodiments, polyurethane thermoplastics sold under the marks TECOFLEX®, CARBOTHANE®, CHRONOFLEX®, and QUADRIFLEX® can be used to form the catheter tube. Note that other suitable, biocompatible materials can also be used. In one embodiment, the catheter tube 12 includes a polyurethane with a 60D Shore hardness, which assists in preventing kinking, enabling power injection therethrough, and improving insertability into the body of a patient in an acute dialysis scenario, for instance. In other non-limiting embodiments, the hardness of the catheter tube can vary from about 55D to about 65D. Desired characteristics for the material from which the catheter body is formed in one embodiment include thermosensitivity such that the material softens after insertion into the patient body, and suitable polymer strength to withstand power injection pressures to which the catheter assembly may be subjected.


In one embodiment, the atraumatic tip of the distal tip region 1350 includes a polyurethane with an 85A Shore hardness. In one non-limiting example, the atraumatic tip can range from 85A to 75A Shore hardness. In one embodiment, the material of the catheter body 1311 and atraumatic tip can include a radiopaque material, such as barium or tungsten, to enable visibility of the catheter assembly under x-ray imaging.



FIG. 25 depicts the catheter body 1311 according to another embodiment, wherein the arterial and venous lumens 1312, 1314 include a differing cross-sectional configuration from that shown in FIG. 24. As shown, the substantially identical arterial and venous lumens 1312, 1314 each cross-sectionally define the major arc 1398 and opposite thereto a flattened side 1402, defined by the septum 1390.



FIG. 26 depicts the catheter body 1311 according to another embodiment, wherein the arterial and venous lumens 1312, 1314 include a differing cross-sectional configuration from that shown in FIG. 24. As shown, a fourth lumen 1410, substantially round in cross-sectional shape, is included. Further, the substantially identical arterial and venous lumens 1312, 1314 each cross-sectionally define the major arc 1398 and opposite thereto a convex portion 1414, defined by the septum 1390. In particular, the septum 1390 includes a centrally disposed unified portion 1390A and a first and second bifurcated portion 1390B, 1390C that are disposed on either side of the unified portion and largely define the third lumen 1315 and fourth lumen 1410.



FIGS. 27 and 28 depict various details of a catheter assembly 1510 according to one embodiment. Note that the embodiments described below include various similarities to the embodiments described above; as such, only selected aspects will be discussed below.


As shown, the catheter assembly 1510 includes an elongate catheter tube, or catheter body 1511, which defines a plurality of lumens extending from a proximal end to a distal end thereof. The proximal end of the catheter body 1511 is operably attached to a bifurcation 1520, which in turn is operably attached to extension legs, namely an arterial extension leg 1516 and a venous extension leg 1518. The number of catheter body lumens, extension legs, and their respective configurations can vary from what is shown and described herein. For instance, though shown in FIG. 27 as straight, the arterial and venous extension legs 1316, 1318 can each be curved in a U-shaped configuration, in one embodiment. These and other modifications are contemplated.


The distal portion of the catheter body 1511 includes features similar to those shown in FIGS. 1-5 (discussed further above), including a tapered distal tip region in contrast to the cylindrically flattened oval-shaped outer surface of the more proximal portion of the catheter body, a venous lateral opening 1560, and an arterial lateral opening 1562. The venous and arterial lateral openings 1560 and 1562 are in fluid communication with respective venous and arterial lumens, which are referenced below and defined by the catheter body 1511. Each of the venous and arterial lateral openings 1560 and 1562 is defined by an angled skive cut so as to impart an angular direction component, with respect to the longitudinal axis of the catheter tube 1511, to fluid entering (via the arterial distal opening) or exiting (via the venous distal opening) the catheter tube, as before.


A distal end opening 1564 is included at the distal end of the distal tip region and is in fluid communication with the venous lumen, described below, though the distal end opening could be in communication with the arterial lumen in another embodiment. In addition, side holes 1542 are included in the catheter body 1511 proximal to the distal tip region, which are in fluid communication with one of the arterial and venous lumens. Such side holes provide an alternate fluid path in addition to the venous and arterial lateral openings 1560, 1562. Note that the particular configuration of the various lateral and side hole openings can vary from what is shown and described herein.



FIG. 28 depicts further details regarding the cross-sectional lumen configuration of the catheter body 1511, according to the present embodiment. As shown, an outer perimeter, or outer wall 1586 having a substantially flattened oval cross-sectional configuration defines the external portion of the catheter 1511. Indeed, the outer wall 1586 bounds a first, arterial lumen 1512 and a second, venous lumen 1514, as mentioned above. A septum 1590 cooperates with the outer wall 1586 to define the particular shape configurations of the two lumens 1512 and 1514, which each substantially extend the longitudinal length of the catheter body 1511. As discussed, the arterial lumen 1512 and the venous lumen 1514 communicate with the arterial lateral opening 1562 and the venous lateral opening 1560, respectively.



FIG. 28 depicts further details regarding the cross-sectional lumen configuration of the catheter body 1511, according to the present embodiment. As shown, the flattened oval outer wall 1586 and the hourglass-shaped septum 1590 of the catheter body 1511 define the arterial lumen 1512 and the venous lumen 1514, as mentioned above. The cross-sectional configurations of the arterial and venous lumens 1512, 1514 are mirror projections of each other as taken across the center line (“CL”) indicated at 1389 in FIG. 28. In particular, both the arterial and venous lumens 1512, 1514 cross-sectionally define a modified ellipse cross-sectional lumen profile. In greater detail, each of the arterial and venous lumens 1512, 1514 cross-sectionally defines a first, minor arc 1594 adjacent and defined by the hourglass-shaped septum 1590, bounded by two corners: a top corner 1596A and a bottom corner 1596B. A second, major arc 1598 extends from each of the corners 1596A, 1596B on a side opposite the septum 1590 and adjacent the outer wall 1586 to define the rest of each lumen 1512, 1514. This configuration interposes both the top corner 1596A and the bottom corner 1596B between the major arc 1598 and the minor arc 1594. The top and bottom corners 1596A and 1596B are substantially rounded to ensure a laminar flow of fluids through the arterial and venous lumens 1512, 1514, thus desirably preventing areas of fluid flow stagnation.


As shown in FIG. 28, the septum 1590 separates the arterial lumen 1512 and the venous lumen 1514. Centered on the center line 1389, the septum 1590 defines an hourglass cross-sectional shape equally distributed about the transverse axis 1388 and helps define the aformentioned shapes of the lumens. Note that the general hourglass configuration of the septum 1590 adds structural strength to the septum.


The cross-sectional configuration shown in FIG. 28 in the present embodiment extends from the proximal end of the catheter body 1511 distally to the arterial and venous lateral openings 1562, 1560, though this can be modified in other embodiments. It is noted that the various cross-sectional features of the catheter body 1511 described immediately above can vary in size, shape, and position from what is shown and described herein.


According to one embodiment, the various features described above include the following cross-sectional dimensions: the perimeter of the outer wall 1386 includes a width of about 0.173 inch and a height of about 0.115 inch; the thickness of the septum 1390 at the transverse axis 1388 is about 0.015 inch; the thickness of outer wall along the major arc 1598 is about 0.010 inch; the radius of the minor arc 1594 is about 0.100 inch; the radius of the major arc 1598 is about 0.050 inch; the width of each lumen 1512, 1514 at the transverse axis 1388 is about 0.072 inch; and the radius of each corner 1596A, 1596B is about 0.016 inch. Note that the above dimensions pertain to a catheter assembly 1510 having an 11 French size; of course, the size of the catheter body and its respective lumens can be scaled as needed/desired. The catheter body 1511 and its atraumatic tip can include suitable materials as have been described further above.


Embodiments of the present invention may be embodied in other specific forms without departing from its spirit or essential characteristics. The described embodiments are to be considered in all respects only as illustrative, not restrictive. The scope of the embodiments of the present invention is, therefore, indicated by the appended claims rather than by the foregoing description. All changes that come within the meaning and range of equivalency of the claims are to be embraced within their scope.

Claims
  • 1. A catheter assembly, comprising: an elongate catheter tube, comprising: an outer surface with opposing flat sides;a first lumen with a first cross-sectional shape and first cross-sectional area;a second lumen with a second cross-sectional shape and second cross-sectional area substantially equivalent to the first cross-sectional shape and the first cross-sectional area;a third lumen with a third cross-sectional shape and a third cross-sectional area, wherein the third cross-sectional area is smaller than the first cross-sectional area and the second cross-sectional area, the third lumen axially offset from a central axis of the elongate catheter tube and adjacent to a first side of the opposing flat sides, the third lumen configured to withstand pressures associated with power injection of a fluid therethrough,wherein the first cross-sectional shape, the second cross-sectional shape, and the third cross-sectional shape are substantially circular;a nose portion joined to a distal end of the elongate catheter tube, the nose portion comprising: a venous lateral opening in fluid communication with the first lumen;an arterial lateral opening in fluid communication with the second lumen; anda distal end opening in fluid communication with the third lumen, wherein the distal end opening is distal of the venous lateral opening and the arterial lateral opening; anda trifurcating hub coupled to a proximal end of the elongate catheter tube, the trifurcating hub providing fluid communication between: a venous extension leg and the first lumen,an arterial extension leg and the second lumen, anda power extension leg and the third lumen.
  • 2. The catheter assembly according to claim 1, wherein the nose portion has a tapered profile defined by a septum between the venous lateral opening and the arterial lateral opening reducing in height between the opposing flat sides in a distal direction.
  • 3. The catheter assembly according to claim 2, wherein the tapered profile extends linearly from a second side of the opposing flat sides to the distal end opening.
  • 4. The catheter assembly according to claim 3, wherein the venous lateral opening and the arterial lateral opening are positioned in an un-staggered position.
  • 5. The catheter assembly according to claim 1, wherein the venous lateral opening and the arterial lateral opening are positioned in an un-staggered position.
  • 6. The catheter assembly according to claim 1, wherein the third lumen is configured to accommodate a flow rate of between about three milliliters per second and about eight milliliters per second.
  • 7. The catheter assembly according to claim 6, wherein the third lumen is configured to accommodate a fluid infusion pressure of between about 50 psi and about 250 psi.
  • 8. The catheter assembly according to claim 7, wherein the power extension leg has a purple color to indicate power injectability.
  • 9. The catheter assembly according to claim 6, wherein the power extension leg has a purple color to indicate power injectability.
  • 10. The catheter assembly according to claim 1, wherein the outer surface of the elongate catheter tube defines a flattened oval cross-sectional shape.
  • 11. The catheter assembly according to claim 1, wherein the fluid is contrast media useful for contrast-enhanced CT scan imaging.
  • 12. The catheter assembly according to claim 11, wherein the power extension leg has a purple color to indicate power injectability.
  • 13. An elongate catheter tube, comprising: an outer surface with opposing flat sides;a first lumen with a first cross-sectional shape and first cross-sectional area;a second lumen with a second cross-sectional shape and second cross-sectional area substantially equivalent to the first cross-sectional shape and the first cross-sectional area; anda third lumen with a third cross-sectional shape and a third cross-sectional area, wherein the third cross-sectional area is smaller than the first cross-sectional area and the second cross-sectional area, the third lumen axially offset from a central axis of the elongate catheter tube and adjacent to a first side of the opposing flat sides, the third lumen configured to withstand pressures associated with power injection of a fluid therethrough; further comprising: a venous lateral opening in fluid communication with the first lumen; an arterial lateral opening in fluid communication with the second lumen; and a distal end opening in fluid communication with the third lumen, wherein the distal end opening is distal of the venous lateral opening and the arterial lateral opening.
  • 14. The elongate catheter tube according to claim 13, wherein the first cross-sectional shape, the second cross-sectional shape, and the third cross-sectional shape are substantially circular.
  • 15. The elongate catheter tube according to claim 13, wherein the venous lateral opening and the arterial lateral opening are positioned in an un-staggered position.
  • 16. The elongate catheter tube according to claim 13, wherein the venous lateral opening, the arterial opening, and the distal end opening are located in a nose portion extending from the distal end of the elongate catheter tube.
  • 17. The elongate catheter tube according to claim 16, wherein the nose portion has a tapered profile defined by a septum between the venous lateral opening and the arterial lateral opening reducing in height between the opposing flat sides in a distal direction.
  • 18. The elongate catheter tube according to claim 17, wherein the tapered profile extends linearly to the distal end opening.
  • 19. The elongate catheter tube according to claim 13, wherein the third lumen is configured to accommodate a flow rate of between about three milliliters per second and about eight milliliters per second.
  • 20. The elongate catheter tube according to claim 13, wherein the third lumen is configured to accommodate a fluid infusion pressure of between about 50 psi and about 250 psi.
  • 21. The elongate catheter tube according to claim 13, wherein the third lumen is configured to accommodate a fluid infusion pressure of at least 300 psi.
  • 22. The elongate catheter tube according to claim 13, wherein the fluid is contrast media useful for contrast-enhanced CT scan imaging.
  • 23. The elongate catheter tube according to claim 13, wherein the elongate catheter tube includes a material having a Shore hardness in a range of about 55D to about 65D.
  • 24. The elongate catheter tube according to claim 23, wherein the elongate catheter tube includes a polyurethane with a Shore hardness of 60D.
  • 25. The elongate catheter tube according to claim 13, wherein the outer surface of the elongate catheter tube defines a flattened oval cross-sectional shape.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a division of U.S. patent application Ser. No. 15/442,608, now U.S. Pat. No. 10,518,064, which is a division of U.S. patent application Ser. No. 14/549,941, filed Nov. 21, 2014, now U.S. Pat. No. 9,579,485, which claims the benefit of U.S. Provisional Application No. 61/907,344, filed Nov. 21, 2013, and which is a continuation-in-part of U.S. patent application Ser. No. 13/329,156, filed Dec. 16, 2011, now U.S. Pat. No. 8,894,601, which is a continuation of U.S. patent application Ser. No. 12/262,820, filed Oct. 31, 2008, now U.S. Pat. No. 8,092,415, which claims the benefit of U.S. Provisional Application No. 60/984,661, filed Nov. 1, 2007. Each of the aforementioned applications is incorporated by reference in its entirety into this application.

US Referenced Citations (703)
Number Name Date Kind
701075 McCully May 1902 A
1696018 Scheliberg Dec 1928 A
1856811 Inaki May 1932 A
2024982 Scott Dec 1935 A
2173527 Agayoff Sep 1939 A
2286462 Chaffin Jun 1942 A
2393002 Smith Jan 1946 A
2748769 Huber Jun 1956 A
2910981 Wilson et al. Nov 1959 A
3144868 Jascalevich Aug 1964 A
3176690 H'Doubler Apr 1965 A
3256885 Higgins et al. Jun 1966 A
3308822 De Luca Mar 1967 A
3416532 Grossman Dec 1968 A
3426759 Smith Feb 1969 A
3460255 Hutson Aug 1969 A
D217795 Spaven Jun 1970 S
3612038 Halligan Oct 1971 A
3736939 Taylor Jun 1973 A
3805794 Schlesinger Apr 1974 A
3812851 Rodriguez May 1974 A
3848604 Sackner Nov 1974 A
3890977 Wilson Jun 1975 A
3929126 Corsaut Dec 1975 A
3935857 Co Feb 1976 A
3995623 Blake et al. Dec 1976 A
4068659 Moorehead Jan 1978 A
4072146 Howes Feb 1978 A
4072153 Swartz Feb 1978 A
4098275 Consalvo Jul 1978 A
4114625 Onat Sep 1978 A
4117836 Erikson Oct 1978 A
4129129 Amrine Dec 1978 A
4134402 Mahurkar Jan 1979 A
4149535 Volder Apr 1979 A
4180068 Jacobsen et al. Dec 1979 A
D254444 Levine Mar 1980 S
4248224 Jones Feb 1981 A
4276880 Malmin Jul 1981 A
4292976 Banka Oct 1981 A
4299228 Peters Nov 1981 A
4300550 Gandi et al. Nov 1981 A
4309994 Grunwald Jan 1982 A
4327722 Groshong et al. May 1982 A
4385631 Uthmann May 1983 A
4392855 Oreopoulos et al. Jul 1983 A
4403983 Edelman et al. Sep 1983 A
4405313 Sisley et al. Sep 1983 A
4406656 Hattler et al. Sep 1983 A
D272651 Mahurkar Feb 1984 S
4431426 Groshong et al. Feb 1984 A
4432722 Bohan, Jr. et al. Feb 1984 A
4432752 Marlon Feb 1984 A
4445893 Bodicky May 1984 A
4451252 Martin May 1984 A
4453928 Steiger Jun 1984 A
4465482 Tittel Aug 1984 A
4490138 Lipsky et al. Dec 1984 A
4493696 Uldall Jan 1985 A
RE31873 Howes Apr 1985 E
4531933 Norton et al. Jul 1985 A
4543087 Sommercorn et al. Sep 1985 A
4545373 Christoudias Oct 1985 A
4549879 Groshong et al. Oct 1985 A
4557261 Rugheimer Dec 1985 A
4568329 Mahurkar Feb 1986 A
4568338 Todd Feb 1986 A
4573476 Ruiz Mar 1986 A
4581012 Brown et al. Apr 1986 A
4583968 Mahurkar Apr 1986 A
4583986 Lapidus Apr 1986 A
4601697 Mammolenti et al. Jul 1986 A
4619643 Bai Oct 1986 A
4623327 Mahurkar Nov 1986 A
4626240 Edelman et al. Dec 1986 A
4642101 Krolikowski et al. Feb 1987 A
4643711 Bates Feb 1987 A
4666426 Aigner May 1987 A
4668221 Luther May 1987 A
4670009 Bullock Jun 1987 A
4675004 Hadford et al. Jun 1987 A
4681122 Winters et al. Jul 1987 A
4681564 Landreneau Jul 1987 A
4681570 Dalton Jul 1987 A
4682978 Martin Jul 1987 A
4687471 Twardowski et al. Aug 1987 A
4692141 Mahurkar Sep 1987 A
4694838 Wijayarthna et al. Sep 1987 A
4701159 Brown et al. Oct 1987 A
4702917 Schindler Oct 1987 A
4706671 Weinrib Nov 1987 A
4713171 Polaschegg Dec 1987 A
4717379 Ekholmer Jan 1988 A
4735620 Ruiz Apr 1988 A
4737141 Spits Apr 1988 A
4737152 Alchas Apr 1988 A
4738667 Galloway Apr 1988 A
4748808 Hill Jun 1988 A
4755176 Patel Jul 1988 A
4769016 Labianca Sep 1988 A
4770652 Mahurkar Sep 1988 A
4772268 Bates Sep 1988 A
4772269 Twardowski et al. Sep 1988 A
4776841 Catalano Oct 1988 A
4777951 Cribier et al. Oct 1988 A
4784638 Ghajar et al. Nov 1988 A
4790809 Kuntz Dec 1988 A
4795439 Guest Jan 1989 A
4801297 Mueller Jan 1989 A
D300060 Molgaard-Nielsen Feb 1989 S
4804359 Grunwald et al. Feb 1989 A
4808155 Mahurkar Feb 1989 A
4808163 Laub Feb 1989 A
4809710 Williamson Mar 1989 A
4820265 DeSatnick et al. Apr 1989 A
4832687 Smith, III May 1989 A
4834709 Banning et al. May 1989 A
4842582 Mahurkar Jun 1989 A
4842592 Caggiani et al. Jun 1989 A
4846814 Ruiz Jul 1989 A
4863441 Lindsay et al. Sep 1989 A
4867742 Calderon Sep 1989 A
4892518 Cupp et al. Jan 1990 A
4894057 Howes Jan 1990 A
4895561 Mahurkar Jan 1990 A
4898591 Jang et al. Feb 1990 A
4906238 Greenfeld et al. Mar 1990 A
4925452 Melinyshyn et al. May 1990 A
4927418 Dake et al. May 1990 A
4935004 Cruz Jun 1990 A
4935010 Cox et al. Jun 1990 A
4935044 Schoenpflug Jun 1990 A
4936826 Amarasinghe Jun 1990 A
4950232 Ruzicka et al. Aug 1990 A
4950259 Geary et al. Aug 1990 A
4951665 Schneider Aug 1990 A
4961729 Vaillancourt Oct 1990 A
4961731 Bodicky et al. Oct 1990 A
4961809 Martin Oct 1990 A
4968307 Dake et al. Nov 1990 A
4969890 Sugita et al. Nov 1990 A
4981477 Schon et al. Jan 1991 A
4985014 Orejola Jan 1991 A
4990138 Bacich et al. Feb 1991 A
4994027 Farrell Feb 1991 A
4995865 Gahara et al. Feb 1991 A
5009636 Wortley et al. Apr 1991 A
5015230 Martin et al. May 1991 A
5016640 Ruiz May 1991 A
5021044 Sharkawy Jun 1991 A
5041101 Seder et al. Aug 1991 A
5041107 Heil, Jr. Aug 1991 A
5049138 Chevalier et al. Sep 1991 A
5053003 Dadson et al. Oct 1991 A
5053004 Markel et al. Oct 1991 A
5053023 Martin Oct 1991 A
5057073 Martin Oct 1991 A
5059170 Cameron Oct 1991 A
5059177 Towne et al. Oct 1991 A
5069673 Shwab Dec 1991 A
5074841 Ademovic et al. Dec 1991 A
5084013 Takase Jan 1992 A
5098412 Shiu Mar 1992 A
5100395 Rosenberg Mar 1992 A
5102402 Dror et al. Apr 1992 A
5106368 Uldall et al. Apr 1992 A
5106376 Mononen et al. Apr 1992 A
5111829 Alvarez de Toledo May 1992 A
5112301 Fenton, Jr. et al. May 1992 A
5114423 Kasprzyk et al. May 1992 A
5117836 Millar Jun 1992 A
5120299 Lombardi Jun 1992 A
5120304 Sasaki Jun 1992 A
5122125 Deuss Jun 1992 A
5125888 Howard et al. Jun 1992 A
5125904 Lee Jun 1992 A
5129891 Young Jul 1992 A
5135599 Martin et al. Aug 1992 A
5139486 Moss Aug 1992 A
5156592 Martin et al. Oct 1992 A
5163928 Hobbs et al. Nov 1992 A
5167623 Cianci et al. Dec 1992 A
5171216 Dasse et al. Dec 1992 A
5171227 Twardowski et al. Dec 1992 A
5178616 Uemiya et al. Jan 1993 A
5188592 Hakki Feb 1993 A
5188593 Martin Feb 1993 A
5190520 Fenton, Jr. et al. Mar 1993 A
5190529 McCrory et al. Mar 1993 A
5191898 Millar Mar 1993 A
5195962 Martin et al. Mar 1993 A
5197951 Mahurkar Mar 1993 A
5197973 Pang et al. Mar 1993 A
5197976 Herweck et al. Mar 1993 A
5201723 Quinn Apr 1993 A
5207648 Gross May 1993 A
5207650 Martin May 1993 A
5209723 Twardowski et al. May 1993 A
5209725 Roth May 1993 A
5209742 Venema et al. May 1993 A
5215527 Beck et al. Jun 1993 A
5221255 Mahurkar et al. Jun 1993 A
5221256 Mahurkar Jun 1993 A
5222949 Kaldany Jun 1993 A
5226880 Martin Jul 1993 A
5234438 Semrad Aug 1993 A
5236016 Vogelsang Aug 1993 A
5242398 Knoll et al. Sep 1993 A
5246430 MacFarlane Sep 1993 A
5250034 Appling et al. Oct 1993 A
5254084 Geary Oct 1993 A
5273527 Schatz et al. Dec 1993 A
5273534 Knoepfler Dec 1993 A
5279596 Castaneda et al. Jan 1994 A
5279599 Wilk Jan 1994 A
5306240 Berry Apr 1994 A
5312337 Flaherty et al. May 1994 A
5312357 Buijs et al. May 1994 A
5318517 Reiman Jun 1994 A
5322519 Ash Jun 1994 A
5324274 Martin Jun 1994 A
5330432 Yoon Jul 1994 A
5338308 Wilk Aug 1994 A
5342295 Imran Aug 1994 A
5342386 Trotta Aug 1994 A
5346471 Raulerson Sep 1994 A
5348536 Young et al. Sep 1994 A
5350358 Martin Sep 1994 A
5360397 Pinchuk Nov 1994 A
5360407 Leonard et al. Nov 1994 A
5364344 Beattie et al. Nov 1994 A
5374245 Mahurkar Dec 1994 A
5378230 Mahurkar Jan 1995 A
5380276 Miller et al. Jan 1995 A
5380290 Makower et al. Jan 1995 A
5382238 Abrahamson et al. Jan 1995 A
5389087 Miraki Feb 1995 A
5389090 Fischell et al. Feb 1995 A
5395316 Martin Mar 1995 A
5399168 Wadsworth, Jr. et al. Mar 1995 A
5403291 Abrahamson Apr 1995 A
5405320 Twardowski et al. Apr 1995 A
5405341 Martin Apr 1995 A
5409463 Thomas et al. Apr 1995 A
5417668 Setzer et al. May 1995 A
5423768 Folden et al. Jun 1995 A
5431661 Koch Jul 1995 A
5451026 Smith Sep 1995 A
5451206 Young Sep 1995 A
5451233 Yock Sep 1995 A
5458570 May, Jr. Oct 1995 A
5458582 Nakao Oct 1995 A
5462533 Daugherty Oct 1995 A
5472417 Martin et al. Dec 1995 A
5472432 Martin Dec 1995 A
5476453 Mehta Dec 1995 A
5480380 Martin Jan 1996 A
5486159 Mahurkar Jan 1996 A
5489278 Abrahamson Feb 1996 A
5496292 Burnham Mar 1996 A
5496872 Constancis et al. Mar 1996 A
5505710 Dorsey, III Apr 1996 A
5507723 Keshaviah Apr 1996 A
5509897 Twardowski et al. Apr 1996 A
5509900 Kirkman Apr 1996 A
5509902 Raulerson Apr 1996 A
5542925 Orth Aug 1996 A
5545373 Maziasz et al. Aug 1996 A
5556390 Hicks Sep 1996 A
5556930 Brehm et al. Sep 1996 A
5558635 Cannon Sep 1996 A
5562609 Brumbach Oct 1996 A
5562696 Nobles et al. Oct 1996 A
5569182 Twardowski et al. Oct 1996 A
5569195 Saab Oct 1996 A
5571093 Cruz et al. Nov 1996 A
5584803 Stevens et al. Dec 1996 A
5599304 Shaari Feb 1997 A
5599328 Stevens Feb 1997 A
5607462 Imran Mar 1997 A
5624392 Saab Apr 1997 A
5624413 Markel et al. Apr 1997 A
5632729 Cai et al. May 1997 A
5637102 Tolkoff et al. Jun 1997 A
5642270 Green et al. Jun 1997 A
5655867 Gysi et al. Aug 1997 A
5662606 Cimino et al. Sep 1997 A
5665067 Linder et al. Sep 1997 A
5674237 Ott Oct 1997 A
5685867 Twardowski et al. Nov 1997 A
5686867 Sutardja et al. Nov 1997 A
5693030 Lee et al. Dec 1997 A
5695457 St. Goar et al. Dec 1997 A
5704915 Melsky et al. Jan 1998 A
5713849 Bosma et al. Feb 1998 A
5713853 Clark et al. Feb 1998 A
5717216 McCoy et al. Feb 1998 A
5718678 Fleming, III Feb 1998 A
5718692 Schon et al. Feb 1998 A
5720735 Dorros Feb 1998 A
5738649 Macoviak Apr 1998 A
5741329 Agrawal et al. Apr 1998 A
5743873 Cai et al. Apr 1998 A
5752939 Makoto May 1998 A
5769796 Palermo et al. Jun 1998 A
5772643 Howell et al. Jun 1998 A
5776096 Fields Jul 1998 A
5776111 Tesio Jul 1998 A
5785686 Runge Jul 1998 A
5792094 Stevens et al. Aug 1998 A
5792123 Ensminger Aug 1998 A
5797869 Martin et al. Aug 1998 A
5800384 Russell et al. Sep 1998 A
5800414 Cazal Sep 1998 A
5800516 Fine et al. Sep 1998 A
5807311 Palestrant Sep 1998 A
5807318 St. Goar et al. Sep 1998 A
5807329 Gelman Sep 1998 A
5809897 Powell et al. Sep 1998 A
5810789 Powers et al. Sep 1998 A
5814016 Valley et al. Sep 1998 A
5830184 Basta Nov 1998 A
5830196 Hicks Nov 1998 A
5833671 Macoviak et al. Nov 1998 A
5843048 Gross Dec 1998 A
5858009 Jonkman Jan 1999 A
5861010 Boussignac et al. Jan 1999 A
5868717 Prosl Feb 1999 A
5873865 Horzewski et al. Feb 1999 A
5876366 Dykstra et al. Mar 1999 A
5876426 Kume et al. Mar 1999 A
5882347 Mouris-Laan et al. Mar 1999 A
5891111 Ismael Apr 1999 A
5904670 Schreiner May 1999 A
5911715 Berg et al. Jun 1999 A
5913848 Luther et al. Jun 1999 A
5916208 Luther et al. Jun 1999 A
5919160 Sanfilippo, II Jul 1999 A
5944732 Raulerson et al. Aug 1999 A
5947937 Urrutia et al. Sep 1999 A
5947953 Ash et al. Sep 1999 A
5957879 Roberts et al. Sep 1999 A
5957893 Luther et al. Sep 1999 A
5957912 Heitzmann Sep 1999 A
5961486 Twardowski et al. Oct 1999 A
5964796 Imran Oct 1999 A
5976103 Martin Nov 1999 A
5976120 Chow et al. Nov 1999 A
5980551 Summers et al. Nov 1999 A
5984908 Davis et al. Nov 1999 A
5989206 Prosl et al. Nov 1999 A
5989213 Maginot Nov 1999 A
6001079 Pourchez Dec 1999 A
6033382 Basta Mar 2000 A
6036654 Quinn et al. Mar 2000 A
6059771 Balbierz et al. May 2000 A
6074374 Fulton Jun 2000 A
6086555 Eliasen et al. Jul 2000 A
6086557 Morejohn et al. Jul 2000 A
6090096 St. Goar et al. Jul 2000 A
6099513 Spehalski Aug 2000 A
6103778 Hyon et al. Aug 2000 A
6106540 White et al. Aug 2000 A
6113572 Gailey et al. Sep 2000 A
6117117 Mauch Sep 2000 A
6120494 Jonkman Sep 2000 A
6126631 Loggie Oct 2000 A
6132425 Gough Oct 2000 A
6143013 Samson et al. Nov 2000 A
6146354 Beil Nov 2000 A
6146373 Cragg et al. Nov 2000 A
6152909 Bagaoisan et al. Nov 2000 A
6156016 Maginot Dec 2000 A
6161547 Barbut Dec 2000 A
6178356 Chastain et al. Jan 2001 B1
6180059 Divino, Jr. et al. Jan 2001 B1
6190349 Ash et al. Feb 2001 B1
6190371 Maginot et al. Feb 2001 B1
6193685 Goodin Feb 2001 B1
6196996 Teirstein Mar 2001 B1
6206849 Martin et al. Mar 2001 B1
6210365 Afzal Apr 2001 B1
6210380 Mauch Apr 2001 B1
6217527 Selmon et al. Apr 2001 B1
6224622 Kotzev May 2001 B1
6238406 Ellis et al. May 2001 B1
6264627 Liska et al. Jul 2001 B1
6273879 Keith et al. Aug 2001 B1
6280413 Clark et al. Aug 2001 B1
6280423 Davey et al. Aug 2001 B1
6287326 Pecor Sep 2001 B1
6293927 McGuckin, Jr. Sep 2001 B1
6293958 Berry et al. Sep 2001 B1
6296631 Chow Oct 2001 B2
6299631 Shalaby Oct 2001 B1
6322551 Brugger Nov 2001 B1
6328730 Harkrider, Jr. Dec 2001 B1
6342120 Basta Jan 2002 B1
6361529 Goodin et al. Mar 2002 B1
6383172 Barbut May 2002 B1
6394141 Wages et al. May 2002 B2
6394142 Woelfel et al. May 2002 B1
6409700 Siegel, Jr. et al. Jun 2002 B1
6413228 Hung et al. Jul 2002 B1
6428513 Abrahamson Aug 2002 B1
6443922 Roberts et al. Sep 2002 B1
6450988 Bradshaw Sep 2002 B1
6453185 O'Keefe Sep 2002 B1
6454997 Divino, Jr. et al. Sep 2002 B1
6455608 Jia et al. Sep 2002 B1
6463335 Munch et al. Oct 2002 B1
6468287 Baugh Oct 2002 B1
6473633 Heil, Jr. et al. Oct 2002 B1
6475207 Maginot et al. Nov 2002 B1
6475209 Larson et al. Nov 2002 B1
6478789 Spehalski et al. Nov 2002 B1
6482169 Kuhle Nov 2002 B1
6533763 Schneiter Mar 2003 B1
6565594 Herweck et al. May 2003 B1
6576001 Werneth et al. Jun 2003 B2
6582459 Lau et al. Jun 2003 B1
6585705 Maginot et al. Jul 2003 B1
6592565 Twardowski Jul 2003 B2
6595966 Davey et al. Jul 2003 B2
6620118 Prosl et al. Sep 2003 B1
6638242 Wilson et al. Oct 2003 B2
6659134 Navis Dec 2003 B2
6682498 Ross Jan 2004 B2
6682519 Schon Jan 2004 B1
6691625 Duncan Feb 2004 B2
6695832 Schon et al. Feb 2004 B2
6702776 Quinn Mar 2004 B2
6712797 Southern, Jr. Mar 2004 B1
6712798 Constantz Mar 2004 B2
6719717 Johnson et al. Apr 2004 B1
6719749 Schweikert et al. Apr 2004 B1
6723084 Maginot et al. Apr 2004 B1
6723114 Shalaby Apr 2004 B2
6730299 Tayot et al. May 2004 B1
6752827 Ross et al. Jun 2004 B2
6755851 Noda et al. Jun 2004 B2
6758836 Zawacki Jul 2004 B2
6786664 Claramunt et al. Sep 2004 B2
6786884 DeCant, Jr. et al. Sep 2004 B1
6796991 Nardeo Sep 2004 B2
6797107 Kotzey Sep 2004 B1
6808510 DiFiore Oct 2004 B1
6814718 McGuckin, Jr. et al. Nov 2004 B2
6819951 Patel et al. Nov 2004 B2
6821287 Jang Nov 2004 B1
6824554 Jang Nov 2004 B1
6835452 Hamerski Dec 2004 B1
6837864 Bertolero et al. Jan 2005 B1
6852079 Miyano Feb 2005 B2
6852097 Fulton, III Feb 2005 B1
6858019 McGuckin, Jr. et al. Feb 2005 B2
6872198 Wilson et al. Mar 2005 B1
6878143 Andersen Apr 2005 B2
6881211 Schweikert et al. Apr 2005 B2
6884253 McFarlane Apr 2005 B1
6911014 Wentling et al. Jun 2005 B2
6913601 St. Goar et al. Jul 2005 B2
6916313 Cunningham Jul 2005 B2
6921396 Wilson et al. Jul 2005 B1
6921411 Yock Jul 2005 B2
6934142 Grosse et al. Aug 2005 B2
6966886 Appling Nov 2005 B2
6969381 Voorhees Nov 2005 B2
6979318 McDonald et al. Dec 2005 B1
6991625 Gately et al. Jan 2006 B1
D515211 Chesnin Feb 2006 S
6997894 Caresio Feb 2006 B2
7008395 Loggie Mar 2006 B1
7011645 McGuckin, Jr. et al. Mar 2006 B2
7018384 Skakoon Mar 2006 B2
7029467 Currier et al. Apr 2006 B2
7066914 Andersen Jun 2006 B2
7066925 Gately et al. Jun 2006 B2
7074213 McGuckin, Jr. et al. Jul 2006 B2
7077829 McGuckin, Jr. et al. Jul 2006 B2
7087053 Vanney Aug 2006 B2
7090654 Lotito et al. Aug 2006 B2
7108674 Quinn Sep 2006 B2
D530420 Chesnin Oct 2006 S
7128734 Wilson et al. Oct 2006 B1
7130700 Gardeski et al. Oct 2006 B2
7141035 Haggstrom Nov 2006 B2
RE39451 Kuhle Dec 2006 E
7182746 Haarala et al. Feb 2007 B2
7300430 Wilson et al. Nov 2007 B2
7322953 Redinger Jan 2008 B2
7347852 Hobbs et al. Mar 2008 B2
7381204 Wilson et al. Jun 2008 B2
7393339 Zawacki et al. Jul 2008 B2
7422571 Schweikert et al. Sep 2008 B2
7465286 Patterson et al. Dec 2008 B2
7485107 DiFiore et al. Feb 2009 B2
7569029 Clark Aug 2009 B2
7575563 Appling Aug 2009 B2
7651482 Harris Jan 2010 B2
7686823 Pingleton et al. Mar 2010 B2
7798999 Bailey et al. Sep 2010 B2
7972465 Patterson et al. Jul 2011 B2
8021321 Zawacki Sep 2011 B2
8066660 Gregersen et al. Nov 2011 B2
8092415 Moehle et al. Jan 2012 B2
8100863 Moehle et al. Jan 2012 B2
8152951 Zawacki et al. Apr 2012 B2
8206371 Nimkar et al. Jun 2012 B2
8292841 Gregersen Oct 2012 B2
8500939 Nimkar et al. Aug 2013 B2
8540661 Gregersen Sep 2013 B2
8597275 Nimkar et al. Dec 2013 B2
8696614 Gregersen et al. Apr 2014 B2
8808227 Zawacki et al. Aug 2014 B2
8894601 Moehle et al. Nov 2014 B2
8992454 Anand Mar 2015 B2
9174019 Gregersen Nov 2015 B2
9233200 Gregersen et al. Jan 2016 B2
9572956 Nimkar et al. Feb 2017 B2
9579485 Oborn et al. Feb 2017 B2
9610422 Moehle et al. Apr 2017 B2
9669149 Anand Jun 2017 B2
9782535 Anand Oct 2017 B2
10105514 Nimkar et al. Oct 2018 B2
10207043 Gregersen Feb 2019 B2
10258732 Gregersen et al. Apr 2019 B2
10258768 Loesener et al. Apr 2019 B2
10518064 Oborn et al. Dec 2019 B2
10857330 Loesener et al. Dec 2020 B2
20010041857 Sansoucy Nov 2001 A1
20010041873 Dopper et al. Nov 2001 A1
20020013569 Sterman et al. Jan 2002 A1
20020026156 Quinn Feb 2002 A1
20020055724 Hughes May 2002 A1
20020086047 Mueller et al. Jul 2002 A1
20020087108 Maginot et al. Jul 2002 A1
20020087145 Ehwald et al. Jul 2002 A1
20020091362 Maginot et al. Jul 2002 A1
20020091430 Dobak et al. Jul 2002 A1
20020099326 Wilson et al. Jul 2002 A1
20020099327 Wilson et al. Jul 2002 A1
20020107506 McGuckin et al. Aug 2002 A1
20020138031 Ross Sep 2002 A1
20020169490 Noda et al. Nov 2002 A1
20020173770 Flory et al. Nov 2002 A1
20020177904 Huxel et al. Nov 2002 A1
20030023198 Twardowski Jan 2003 A1
20030032734 Roby Feb 2003 A1
20030088213 Schweikert et al. May 2003 A1
20030093027 McGuckin et al. May 2003 A1
20030097091 Hobbs et al. May 2003 A1
20030135147 Rosenberg et al. Jul 2003 A1
20030144623 Heath et al. Jul 2003 A1
20030149395 Zawacki Aug 2003 A1
20030153898 Schon et al. Aug 2003 A1
20030163145 Raulerson Aug 2003 A1
20030187411 Constantz Oct 2003 A1
20030204179 Davey et al. Oct 2003 A1
20040039350 McKittrick Feb 2004 A1
20040054321 Schon et al. Mar 2004 A1
20040059314 Schon et al. Mar 2004 A1
20040064086 Gottlieb Apr 2004 A1
20040065333 Wilson et al. Apr 2004 A1
20040075198 Schweikert et al. Apr 2004 A1
20040087892 Cunningham May 2004 A1
20040092863 Raulerson et al. May 2004 A1
20040097863 Appling May 2004 A1
20040097903 Raulerson May 2004 A1
20040122418 Voorhees Jun 2004 A1
20040147903 Latini Jul 2004 A1
20040167463 Zawacki et al. Aug 2004 A1
20040171997 Wilson et al. Sep 2004 A1
20040172003 Wilson et al. Sep 2004 A1
20040176739 Stephens et al. Sep 2004 A1
20040193102 Haggstrom Sep 2004 A1
20040197301 Zhao et al. Oct 2004 A1
20040210180 Altman Oct 2004 A1
20040210187 Zawacki Oct 2004 A1
20040210237 Ross et al. Oct 2004 A1
20040220550 Schryver Nov 2004 A1
20040230204 Wortley et al. Nov 2004 A1
20040243095 Nimkar et al. Dec 2004 A1
20040249337 DiFiore Dec 2004 A1
20050003322 Logan et al. Jan 2005 A1
20050004504 Frye et al. Jan 2005 A1
20050013341 Baghai Jan 2005 A1
20050019382 Kummer et al. Jan 2005 A1
20050025641 Shibata et al. Feb 2005 A1
20050027282 Schweikert et al. Feb 2005 A1
20050027289 Castellano et al. Feb 2005 A1
20050033222 Haggstrom et al. Feb 2005 A1
20050033264 Redinger Feb 2005 A1
20050054989 McGuckin et al. Mar 2005 A1
20050055012 Trerotola Mar 2005 A1
20050059925 Maginot et al. Mar 2005 A1
20050070842 Lotito et al. Mar 2005 A1
20050080398 Markel et al. Apr 2005 A1
20050085765 Voorhees Apr 2005 A1
20050096585 Schon et al. May 2005 A1
20050113904 Shank et al. May 2005 A1
20050131341 McGuckin et al. Jun 2005 A1
20050171469 Cunningham Aug 2005 A1
20050187535 Wilson et al. Aug 2005 A1
20050209582 Quinn et al. Sep 2005 A1
20050215977 Uschold Sep 2005 A1
20050228339 Clark Oct 2005 A1
20050240165 Miki et al. Oct 2005 A1
20050245900 Ash Nov 2005 A1
20050251190 McFarlane Nov 2005 A1
20050256461 DiFiore et al. Nov 2005 A1
20050261663 Patterson et al. Nov 2005 A1
20050267400 Haarala et al. Dec 2005 A1
20050277862 Anand Dec 2005 A1
20050283111 Maurice Dec 2005 A1
20050288623 Hjalmarsson Dec 2005 A1
20050288706 Widomski et al. Dec 2005 A1
20060004316 Difiore et al. Jan 2006 A1
20060004325 Hamatake et al. Jan 2006 A1
20060009783 Rome et al. Jan 2006 A1
20060015072 Raulerson Jan 2006 A1
20060015130 Voorhees et al. Jan 2006 A1
20060030827 Raulerson et al. Feb 2006 A1
20060047267 Gately et al. Mar 2006 A1
20060047268 Stephens Mar 2006 A1
20060058775 Stevens et al. Mar 2006 A1
20060064072 Gately et al. Mar 2006 A1
20060095062 Stephens May 2006 A1
20060100572 DiMatteo et al. May 2006 A1
20060111537 Roby May 2006 A1
20060116629 Tal et al. Jun 2006 A1
20060161100 Hamboly Jul 2006 A1
20060184142 Schon et al. Aug 2006 A1
20060189922 Amarasinghe et al. Aug 2006 A1
20060200111 Moehle et al. Sep 2006 A1
20060206094 Chesnin et al. Sep 2006 A1
20060251612 Kotzev et al. Nov 2006 A1
20060253063 Schweikert Nov 2006 A1
20060271012 Canaud et al. Nov 2006 A1
20070005003 Patterson et al. Jan 2007 A1
20070019181 Sinclair et al. Jan 2007 A1
20070066964 Atkins Mar 2007 A1
20070078478 Atkins et al. Apr 2007 A1
20070106206 Appling May 2007 A1
20070129704 O'Mahony et al. Jun 2007 A1
20070167925 Jacqmein Jul 2007 A1
20070191810 Kennedy Aug 2007 A1
20070225661 Ash et al. Sep 2007 A1
20070225682 Ash et al. Sep 2007 A1
20070282274 Chesnin Dec 2007 A1
20080021417 Zawacki et al. Jan 2008 A1
20080039774 Zawacki et al. Feb 2008 A1
20080065029 Racz Mar 2008 A1
20080082079 Braga et al. Apr 2008 A1
20080082080 Braga Apr 2008 A1
20080097409 Stephens Apr 2008 A1
20080172012 Hiniduma-Lokuge et al. Jul 2008 A1
20080214980 Anand Sep 2008 A1
20080214992 Haarala et al. Sep 2008 A1
20090112153 Gregersen et al. Apr 2009 A1
20090118661 Moehle et al. May 2009 A1
20090118701 Nimkar et al. May 2009 A1
20090118707 Schweikert et al. May 2009 A1
20090118755 Maliglowka et al. May 2009 A1
20090138034 Maliglowka et al. May 2009 A1
20090157051 Appling et al. Jun 2009 A1
20090187141 Lareau et al. Jul 2009 A1
20090192435 Gregersen Jul 2009 A1
20090204052 Nimkar et al. Aug 2009 A1
20090204079 Nimkar et al. Aug 2009 A1
20090204083 O'Donnell et al. Aug 2009 A1
20090205189 Nimkar et al. Aug 2009 A1
20090209940 Nimkar et al. Aug 2009 A1
20090292248 Schon et al. Nov 2009 A1
20090312687 DeFonzo et al. Dec 2009 A1
20100081986 Matson et al. Apr 2010 A1
20100331780 Bellisario et al. Dec 2010 A1
20110020418 Bosley, Jr. et al. Jan 2011 A1
20110301522 DeFonzo Dec 2011 A1
20120059304 Gregersen et al. Mar 2012 A1
20120089070 Moehle et al. Apr 2012 A1
20130018405 Onishi et al. Jan 2013 A1
20130079752 Gregersen Mar 2013 A1
20130253445 Nimkar et al. Sep 2013 A1
20130261605 Gregersen et al. Oct 2013 A1
20140018772 Ash Jan 2014 A1
20140025042 Gregersen Jan 2014 A1
20140088510 Nimkar et al. Mar 2014 A1
20140228742 Gregersen et al. Aug 2014 A1
20140276472 VanderStek et al. Sep 2014 A1
20140276493 Leung et al. Sep 2014 A1
20140277052 Haselby et al. Sep 2014 A1
20140330220 Zawacki et al. Nov 2014 A1
20140336687 Iwase et al. Nov 2014 A1
20150073336 Moehle et al. Mar 2015 A1
20150088100 Oborn et al. Mar 2015 A1
20150335810 Anand Nov 2015 A1
20170151418 Nimkar et al. Jun 2017 A1
20170165453 Oborn et al. Jun 2017 A1
20190167888 Gregersen Jun 2019 A1
20190240393 Gregersen et al. Aug 2019 A1
20190240453 Loesener et al. Aug 2019 A1
20220273858 Gregersen et al. Sep 2022 A1
Foreign Referenced Citations (63)
Number Date Country
834211 Feb 1976 BE
1150122 Jul 1983 CA
2474351 Aug 2003 CA
2788836 Jun 2006 CN
101918067 Dec 2010 CN
103170050 Jun 2013 CN
8815869 Feb 1989 DE
9108132 Sep 1991 DE
102005051211 May 2007 DE
0030854 Jun 1981 EP
0132344 Jan 1985 EP
0301854 Feb 1989 EP
0332366 Sep 1989 EP
0386408 Sep 1990 EP
0453234 Oct 1991 EP
0476796 Mar 1992 EP
0495263 Jul 1992 EP
0650740 May 1995 EP
0711574 May 1996 EP
1471966 Nov 2004 EP
1599247 Nov 2005 EP
2305337 Apr 2011 EP
1503469 Mar 1978 GB
101918066 Jul 2013 IN
56-136569 Oct 1981 JP
8-510935 Nov 1996 JP
2001137350 May 2001 JP
2008500081 Jan 2008 JP
2011-502583 Jan 2011 JP
4827377 Nov 2011 JP
45923 Jun 2005 RU
459237 Feb 1975 SU
1991008132 Jun 1991 WO
1993016741 Sep 1993 WO
1993016752 Sep 1993 WO
1997009086 Mar 1997 WO
1997017102 May 1997 WO
1997022374 Jun 1997 WO
1997037699 Oct 1997 WO
1999004844 Feb 1999 WO
2000023137 Apr 2000 WO
WO-0151116 Jul 2001 WO
2002018004 Mar 2002 WO
2002058776 Aug 2002 WO
2002083223 Oct 2002 WO
2003030960 Apr 2003 WO
2003033049 Apr 2003 WO
2003066148 Aug 2003 WO
2004075962 Sep 2004 WO
2004096334 Nov 2004 WO
2004112876 Dec 2004 WO
2005018712 Mar 2005 WO
2005023336 Mar 2005 WO
2005077449 Aug 2005 WO
2005084741 Sep 2005 WO
2005118039 Dec 2005 WO
2006034877 Apr 2006 WO
2008048183 Apr 2008 WO
2009051967 Apr 2009 WO
2009055332 Apr 2009 WO
2009059220 May 2009 WO
2015077560 May 2015 WO
2016011091 Jan 2016 WO
Non-Patent Literature Citations (267)
Entry
U.S. Appl. No. 14/991,858, filed Jan. 8, 2016 Non-Final Office Action dated May 17, 2018.
U.S. Appl. No. 14/991,858, filed Jan. 8, 2016 Notice of Allowance dated Nov. 26, 2018.
U.S. Appl. No. 15/429,049, filed Feb. 9, 2017 Non-Final Office Action dated Mar. 20, 2018.
U.S. Appl. No. 15/429,049, filed Feb. 9, 2017 Notice of Allowance dated May 31, 2018.
U.S. Appl. No. 15/442,608, filed Feb. 24, 2017 Non-Final Office Action dated May 9, 2019.
U.S. Appl. No. 15/442,608, filed Feb. 24, 2017 Notice of Allowance dated Aug. 27, 2019.
US Patent File History U.S. Pat. No. 5,403,291 (Abrahamson), issued Apr. 4, 1995.
US Patent File History U.S. Pat. No. 5,489,278 (Abrahamson), issued Feb. 6, 1996.
US Patent File History U.S. Pat. No. 5,685,867 (Twardowski et al.), issued Nov. 11, 1997.
Wechsler, et al., Thrombosis and Infection Caused by Thoracic Venous Catheters: Pathogenesis and Imagings Findings, AJR, 1993; 160:467-471.
Weitzel, et al., Successful Use of Indwelling Cuffed Femoral Vein Catheters in Ambulatory Hemodialysis Patients, American Journal of Kidney Diseases, 1993, vol. 22, No. 3, pp. 426-429.
Gallichio, et al., Placement of a Double Lumen Silastic Catheter for Hemodialysis Access Through The Cephalic Vein, Journal of the American College of Surgeons, 1994, vol. 179, pp. 171-172.
Gravenstein, et al., In Vitro Evaluation of Relative Perforating Potential of Central Venous Catheters: Comparison of Materials, Selected Models, Number of Lumens, and Angles of Incidence to Simulated Membrane, Journal of Clinical Monitoring, 1991, vol. 7, pp. 1-6.
Haindl, H., Technical complications of port-catheter systems, Reg. Cancer Treat, 1989, 2:238-242.
Haire, et al., Thrombotic Complications of Subclavian Apheresis catheters in Cancer Patients: Prevention With Heparin Infusion, Journal of Clinical Apheresis, 1990, vol. 5, pp. 188-191.
Hull, et al., The Groshong Catheter: Initial Experience and Early Results of Imaging-guided Placement1, Radiology, 1992, vol. 185, pp. 803-807.
Ignotus, et al., Review of Radiological Insertion of Indwelling Central Venous Catheters, Minimally Invasive Therapy, 1992, 1:373-388.
Instructions For Use (Copyright Dated 1990) for Polycath Polyurethance Central Venous Catheter, believed to have been packaged with product and sold in the United States before Jan. 4, 2000 and with related marketing materials.
Instructions for Use (Copyright Dated 1992) for FloLock Single Lumen Bi-directional Valved Catheter; believed to have been packaged with product and sold in the United States before Jan. 2000.
Instructions for Use (not dated) for Infuse-a-Cath Polyurethance Central Venous Catheter; believed to have been backaged with product and sold in the United States before Jan. 2000.
Instructions For Use for Diatek Cannon Catheter Product First Sold in the United States in Sep. 2001.
Jones, et al., Efficacy of the Supraclavicular Route for Temporary Hemodialysis Access, Southern Medical Journal, 1992, vol. 85, No. 7, pp. 725-726.
JP 2010-532299 filed Apr. 30, 2010 Final Notice of Reason for Rejection dated Feb. 8, 2013.
JP 2010-532299 filed Apr. 30, 2010 Official Action dated Apr. 23, 2012.
JP 2016-533038 filed May 20, 2016 Office Action dated Oct. 11, 2018.
JP App. No. 2003-565569 filed Feb. 7, 2003, Translated Decision of Refusal dated Dec. 24, 2009.
JP App. No. 2003-565569 filed Feb. 7, 2003, Translated Official Action dated May 28, 2009.
JP App. No. 2003-565569 filed Feb. 7, 2003, Translated Official Action dated Nov. 7, 2008.
Kapoian et al. Dialysis as Treatment of End-Stage Renal Disease, Chapter 5: Dialysis Access and Recirculation, © 1999.
Kaupke, et al., Perforation of the Superior Vena Cava By a Subclavian Hemodialysis Catheter: early detection by angiography, The International Journal of Artificial Organs, 1992, vol. 15, No. 11, pp. 666-668.
Kelber, et al., Factors Affecting Delivery of High-Efficiency Dialysis Using Temporary Vascular Access, American Journal of Kidney Diseases, 1993, vol. 22, No. 1, pp. 24-29.
Lubrizol, “Lubrizol's Family of TPUs” Brochure (2005), 9 pages.
Lumsden, et al., Hemodialysis Access in the Pediatric Patient Population, The American Journal of Surgery, 1994, vol. 168, pp. 197.
Lund, “Percutaneous Translumbar Inferior Vena Cava Cannulation and other Alternative Vascular Access Techniques” in Venous Interventional Radiology with Clinical Perspectives, Savader et al, eds. pp. 251-261, Apr. 10, 2000.
Lund, et al., Percutaneous Translumbar Inferior Vena Cava Cannulation for Hemodialysis, American Journal of Kidney Diseases, 1995, vol. 25, No. 5, pp. 732-737.
Maki, D., Pathogenesis, Prevention, and Management of Infections Due to Intravascular Devices Used for Infusion Therapy, in Infections Associated with Indwelling Medical Devices, Bisno et al., eds, American Society for Microbiology, 1989, pp. 161-177.
Malviya et al., “Vascular Access in Gynecological Cancer Using the Groshong Right Atrial Catheter”, Gynecological Oncology 33, 313-316 (1989).
Mauro, et al., Radiologic Placement of Long-term Central Venous Catheters: A Review, JVIR, 1993, vol. 4, No. 1, pp. 127-137.
McGee, et al., Accurate placement of central venous catheters: A prospective, randomized, multicenter trial, Critical Care Medicine, 1993, vol. 21, No. 8, pp. 1118-1123.
Medcomp, For Access via the Internal Jugular Vein . . . The Medcomp TESIO Catheter is the Solution: The Short and Long Term Solution to Subclavian Venin Stenosis and Difficult Access Problems, Brochure, 4 pages, 1991.
Medcomp® Brochure , “Ash Split Cath™ XL”, Dec. 2001, PN 2291.
Medcomp® Brochure , “Ash Split Cath™”, Guidewire Weave Insertion Technique, Jan. 2002, PN 2296.
Medcomp® Brochure , “Ash Split Cath™”, Jul. 2001, PN 2114.
Medcomp® Brochure , “Ash Split Cath™”, Nov. 1997, PN 2050.
Medcomp® Brochure , “Ash Split Cath® II”, Aug. 2002, PN 2334.
Medcomp® Brochure , “Magna™ High Flow Catheter”, Mar. 2002, PN 2321.
Moss et al, Use of Silicone Dual-Lumen Catheter with a Dacron Cuff as a Long Term Vascular Access for Hemodialysis Patients, Amer J Kidney Diseases, vol. XVI, No. 3, pp. 211-215, Sep. 1990.
Moss, et al., Use of a Silicone Catheter With a Dacron Cuff for Dialysis Short-Term Vascular Access, American Journal of Kidney Diseases, 1988, vol. XII, No. 6, pp. 492-498.
Myers, R.D. et al, New Double-lumen Polyethylene Cannula for Push-pull Perfusion of Brain Tissue in Vivo, Journal of Neuroscience Methods, pp. 205-218, vol. 12, 1985.
Northsea, C., Using Urokinase to Restore Patency in Double Lumen Catheters, ANNA Journal 1994, vol. 21, No. 5, pp. 261-273.
Origen, OriGen Biomedical Dual Lumen Catheter, from <http://origen.net/catheter.html>, downloaded May 13, 2009, 4 pages (reprinted for submission on Jul. 21, 2011).
Parsa, et al., Establishment of Intravenous Lines for Long-term Intravenous Therapy and Monitoring, Surgical Clinics of N. Am. 1985, vol. 65, No. 4, pp. 835-865.
Parsa, et al., Vascular Access Techniques, Textbook of Critical Care, W.B. Saunders, Philadelphia, PA (1989), pp. 122-127.
Pasquale, et al., Groshong® Versus Hickman® Catheters, Surgery, Gynecology & Obstetrics, 1992, vol. 174, pp. 408-410.
Passaro, et al., Long-term Silastic Catheters and Chest Pain, Journal of Parenteral and Enteral Nutrition, 1994, vol. 18, No. 3, pp. 240-242.
Patel et al., “Sheathless Technique of Ash Split-Cath Insertion”, 12 JVIR 376-78 (Mar. 2001).
Paulsen, et al., Use of Tissue Plasminogen Activator for Reopening of Clotted Dialysis Catheters, Nephron, 1993, vol. 64, pp. 468-470.
PCT/US15/40463 filed Jul. 14, 2015 International Search Report and Written Opinion dated Dec. 18, 2015.
PCT/US2003/003751 filed Feb. 7, 2003 Preliminary Examination Report dated May 5, 2004.
PCT/US2003/003751 filed Feb. 7, 2003 Search Report dated Jul. 3, 2003.
PCT/US2004/005102 filed Feb. 19, 2004 Preliminary Report Patenability dated Aug. 29, 2005.
U.S. Appl. No. 16/163,372, filed Oct. 17, 2018 Non-Final Office Action dated May 14, 2020.
U.S. Appl. No. 16/163,372, filed Oct. 17, 2018 Notice of Allowance dated Aug. 19, 2020.
U.S. Appl. No. 16/270,044, filed Feb. 7, 2019 Non-Final Office Action dated Jun. 9, 2021.
U.S. Appl. No. 16/384,509, filed Apr. 15, 2019 Notice of Allowance dated Sep. 9, 2020.
Arrow Cannon II Plus Brochure, 2006.
Arrow International, Inc. et al v. Spire Biomedical, Inc., U.S. Dist Ct Dist MA CA No. 06-CV-11564-DPW, Declaration of Dr. Karim Valji (Jul. 17, 2008).
Arrow International, Inc. et al v. Spire Biomedical, Inc., U.S. Dist Ct Dist MA CA No. 06-CV-11564-DPW, Declaration of Kenneth Todd Cassidy (Jul. 16, 2008).
Arrow International, Inc. et al v. Spire Biomedical, Inc., U.S. Dist Ct Dist MA CA No. 06-CV-11564-DPW, Declaration of Rebecca R. Eisenberg in Opposition to Defendant's Motion for Partial Summary Judgment of Invalidity (Jun. 8, 2009).
Arrow International, Inc. et al v. Spire Biomedical, Inc., U.S. Dist Ct Dist MA CA No. 06-CV-11564-DPW, Memorandum of Law in Support of Defendant's Motion for Summary Judgment on Invalidity [Redacted Pursuant to Jun. 10, 2008 Order on Motion to Seal].
Arrow International, Inc. et al v. Spire Biomedical, Inc., U.S. Dist Ct Dist MA CA No. 06-CV-11564-DPW, Memorandum of Law in Support of Defendant's Motion for Summary Judgment on Invalidity Exhibit A (Jul. 10, 2009).
Arrow International, Inc. et al v. Spire Biomedical, Inc., U.S. Dist Ct Dist MA CA No. 06-CV-11564-DPW, Plaintiff's Memorandum in Opposition to Defendant's Motion for Summary Judgement on Non-Infringement (Jul. 17, 2008).
Arrow International, Inc. et al v. Spire Biomedical, Inc., U.S. Dist. Ct. Dist. MA CA No. 06-CV-11564-DPW, Defendant's Omnibus Statement of Material Facts in Support of its Motions for Summary Judgment (Jun. 10, 2008) [Redacted Pursuant to Jun. 10, 2008 Order on Motion to Seal].
Bander, et al., Central Venous Angioaccess for Hemodialysis and Its Complications, Seminars in Dialysis, 1992, vol. 5, No. 2, pp. 121-128.
Baranowski, L., Central Venous Access Devices, Journal of Intravenous Nursing, 1993, vol. 16, No. 3, pp. 167-194.
Bard Access Systems Hickman®, Leonard®, and Broviac® Central Venous Catheters (Long Term), Instructions for Use, 31 pages, 1999.
Bard Access Systems Hickman®, Leonard®, and Broviac® Central Venous Catheters, Nursing Procedural Manual, 52 pages, Jun. 1994.
Bard Davol® Hickman® Round Dual Lumen Catheters for Central Venous Access Informational Brochure, 4 pages, 1994.
Bard Hickman® Catheters Informational Brochure, 3 pages, 1994.
Believed to be an unpublished sketch of a conception by Dr. John Frusha; date of sketch believed to be Jun. 24, 1997.
Berkoben, et al., Maintenance of Permanent Hemodialysis Vascular Access Patency, ANNA Journal, 1995, vol. 22, No. 1, pp. 17-24.
Bolz, et al., Catheter Malfunction and Thrombus Formation on Double-Lumen Hemodialysis Catheters: An Intravascular Ultrasonographic Study, American Journal of Kidney Diseases, 1995, vol. 25, No. 4, pp. 597-602.
Bour, et al., Experience With The Double Lumen Silastic® Catheter For Hemoaccess, Surgery, Gynecology & Obstetrics, 1990, vol. 171, pp. 33-39.
Camp, “Care of the Groshong Catheter”, Oncol Nurs Forum, vol. 15, No. 6, 1988.
Campbell, et al., Radiological Insertion of Long-term Venous Access Devices, Seminars in Interventional Radiology, 1994, vol. II, No. 4, pp. 366-375.
Canaud, B et al, Permenant Twin Catheter: A Vascular Access Option of Choice for Haemodialysis in Elderly Patients, pp. 82-88, vol. 17 No. 7, 1994.
Claim Construction Order of Federal District Court dated May 9, 2003 in Thierry Pourchez and Bard Access Systems, Inc. v. Diatek, Inc. and Arrow International, Inc. litigation (S.D. N.Y. 03 Civ.0972).
Claim Construction Order of Federal District Court dated Oct. 31, 2006 in Arrow Int'l. Inc.and Arrow Int'l. Investment Corp. v. Spire Biomedical, Inc. litigation (D. Mass. Civil Action No. 06-CV-11564).
CN 200880121182.0 filed Oct. 20, 2008 First Office Action dated May 2, 2012.
CN 200880121183.5 filed Oct. 2, 2008 First Office Action dated Mar. 28, 2012.
CN 200880121183.5 filed Oct. 2, 2008 Second Office Action dated Aug. 17, 2012.
CN 200880121183.5 filed Oct. 2, 2008 Third Office Action dated Dec. 11, 2012.
CN 200880123095.9 filed Oct. 20, 2008 First Office Action dated Feb. 13, 2012.
CN 200880123095.9 filed Oct. 20, 2008 Second Office Action dated Dec. 18, 2012.
CN 200880123533.1 filed Jun. 30, 2008 First Office Action dated May 28, 2012.
CN 200880123533.1 filed Jun. 30, 2008 Notice of Grant dated Dec. 24, 2012.
CN 201310073124.8 filed Mar. 7, 2013 First Office Action dated May 5, 2014.
Decision of Federal District Court dated Jul. 7, 2009 granting Summary Judgement of Invalidity in Arrow Int'l. Inc.and Arrow Int'l. Investment Corp. v. Spire Biomedical, Inc. litigation (D. Mass. Civil Action No. 06-CV-11564).
Declaration of Gregory S. Haas (Plaintiff's Exhibit 88 in Haas Deposition), Mar. 13, 2003, Thierry Pourchez and Bard Access Systems, Inc. v. Diatek, Inc. and Arrow International, Inc., Civil Action No. 03-CV-0972 (S.D.N.Y.).
Defendant's Exhibits DX78-DX114, Thierry Pourchez and Bard Access Systems, Inc. v. Diatek, Inc. and Arrow International, Inc., Civil Action No. 03-CV-0972 (S.D.N.Y.), 2003.
Defendants' Reponses and Objections to Plaintiffs' Second Set of Interrogatories (Excerpt), Thierry Pourchez and Bard Access Systems, Inc. v. Diatek, Inc. and Arrow International, Inc., Civil Action No. 03-CV-0972 (S.D.N.Y.) (Oct. 8, 2003).
Delmore et al., “Experience with the Groshong Long-Term Central Venous Catheter”, Gynecologic Oncology 34, 216-218 (1989).
Dialysis Vascular Access, SchonXL® Temporary Dialysis (AngioDynamics Inc.) brochure, Nov. 1998.
Dialysis Vascular Access, Technological Innovations Improving Flow (AngioDynamics Inc.) Brochure, 4 pages, Nov. 1998.
DiFiore, “Central Venous Dialysis Catheter Evaluatio in Swine”, Journal of Vascular Access Devices, Fall 2000.
Donaldson, et al., Peripherally Inserted Central Venous Catheters: US-guided Vascular Access in Pediatric Patients1, Radiology, 1995, vol. 197, pp. 542-544.
Dunea, et. al., A Survey of Permanent Double Lumen Catheters in Hemodialysis Patients. ASAIO Transac. 1991; 37: M276-7.
Dupont et al, Long-term development of Permacath Quinton catheters used as a vascular access route for extra-renal detoxification; Néphrologie, vol. 15, pp. 105-110, 1994.
EP 04712925.9 filed Feb. 19, 2004 Office Action dated Nov. 7, 2008.
EP 08839196.6 filed Oct. 2, 2008 Examination Report dated Jan. 16, 2013.
EP 08839196.6 filed Oct. 2, 2008 Search Opinion dated Jul. 12, 2011.
EP 08839196.6 filed Oct. 2, 2008 Search Report dated Jul. 12, 2011.
EP 08872340.8 filed Oct. 2, 2008 Extended European Search Report and an Opinion dated Apr. 19, 2012.
EP 14864273.9 filed May 20, 2016 Extended European Search Report dated Jun. 9, 2017.
EP 14864273.9 filed May 20, 2016 Partial European Search Report dated Jun. 9, 2017.
U.S. Appl. No. 12/244,514, filed Oct. 2, 2008 Advisory Action dated Sep. 5, 2012.
U.S. Appl. No. 12/244,514, filed Oct. 2, 2008 Final Office Action dated Jul. 11, 2011.
U.S. Appl. No. 12/244,514, filed Oct. 2, 2008 Final Office Action dated Jun. 19, 2012.
U.S. Appl. No. 12/244,514, filed Oct. 2, 2008 Non-Final Office Action dated Jan. 19, 2011.
U.S. Appl. No. 12/244,544, filed Oct. 2, 2008 Final Office Action dated Jul. 11, 2011.
U.S. Appl. No. 12/244,544, filed Oct. 2, 2008 Non-Final Office Action dated Dec. 22, 2010.
U.S. Appl. No. 12/244,554, filed Oct. 2, 2008 Final Office Action dated Dec. 27, 2010.
U.S. Appl. No. 12/244,554, filed Oct. 2, 2008 Non-Final Office Action dated Jul. 6, 2010.
U.S. Appl. No. 12/253,870, filed Oct. 17, 2008 Non-Final Office Action dated Jan. 21, 2011.
U.S. Appl. No. 12/253,870, filed Oct. 17, 2008 Notice of Allowance dated Aug. 19, 2011.
U.S. Appl. No. 12/262,820, filed Oct. 31, 2008 Non-Final Office Action dated Feb. 18, 2011.
U.S. Appl. No. 12/262,820, filed Oct. 31, 2008 Notice of Allowance dated Sep. 28, 2011.
U.S. Appl. No. 12/263,141, filed Oct. 31, 2008 Advisory Action dated Aug. 17, 2011.
U.S. Appl. No. 12/263,141, filed Oct. 31, 2008 Final Office Action dated May 26, 2011.
U.S. Appl. No. 12/263,141, filed Oct. 31, 2008 Non-Final Office Action dated Jan. 5, 2011.
U.S. Appl. No. 12/414,467, filed Mar. 30, 2009 Final Office Action dated Feb. 7, 2012.
U.S. Appl. No. 12/414,467, filed Mar. 30, 2009 Notice of Allowance dated May 31, 2012.
U.S. Appl. No. 12/414,467, filed Mar. 30, 2009 Non-Final Office Action dated Aug. 11, 2011.
U.S. Appl. No. 13/294,941, filed Nov. 11, 2011 Non-Final Office Action dated May 27, 2016.
U.S. Appl. No. 13/294,941, filed Nov. 11, 2011 Non-Final Office Action dated May 31, 2013.
U.S. Appl. No. 13/294,941, filed Nov. 11, 2011 Notice of Allowance dated Nov. 27, 2013.
U.S. Appl. No. 13/329,156 filed Dec. 16, 2011 Non-Final Office Action dated May 16, 2014.
U.S. Appl. No. 13/445,713, filed Apr. 12, 2012 Advisory Action dated Aug. 8, 2013.
U.S. Appl. No. 13/445,713, filed Apr. 12, 2012 Final Office Action dated May 30, 2013.
U.S. Appl. No. 13/445,713, filed Apr. 12, 2012 Non-Final Office Action dated Jan. 2, 2013.
U.S. Appl. No. 13/445,713, filed Apr. 12, 2012 Notice of Allowance dated Oct. 18, 2013.
U.S. Appl. No. 13/897,292, filed May 17, 2013 Decision on Appeal dated Jun. 8, 2017.
U.S. Appl. No. 13/897,292, filed May 17, 2013 Final Office Action dated Apr. 9, 2015.
U.S. Appl. No. 13/897,292, filed May 17, 2013 Non-Final Office Action dated Nov. 20, 2014.
U.S. Appl. No. 13/897,292, filed May 17, 2013 Notice of Allowance dated Aug. 23, 2017.
U.S. Appl. No. 14/032,858, filed Sep. 20, 2013 Final Office Action dated Mar. 31, 2015.
U.S. Appl. No. 14/032,858, filed Sep. 20, 2013 Non-Final Office Action dated Nov. 4, 2014.
U.S. Appl. No. 14/032,858, filed Sep. 20, 2013, Notice of Allowance dated Jun. 26, 2015.
U.S. Appl. No. 14/094,534, filed Dec. 2, 2013 Final Office Action dated Jul. 20, 2016.
U.S. Appl. No. 14/094,534, filed Dec. 2, 2013 Non-Final Office Action dated Feb. 24, 2016.
U.S. Appl. No. 14/094,534, filed Dec. 2, 2013 Notice of Allowance dated Sep. 30, 2016.
U.S. Appl. No. 14/252,567, filed Apr. 14, 2014 Non-Final Office Action dated Mar. 31, 2015.
U.S. Appl. No. 14/252,567, filed Apr. 14, 2014 Notice of Allowance dated Sep. 3, 2015.
U.S. Appl. No. 14/328,541, filed Jul. 10, 2014 Final Office Action dated Oct. 22, 2015.
U.S. Appl. No. 14/328,541, filed Jul. 10, 2014 Non-Final Office Action dated Apr. 9, 2015.
U.S. Appl. No. 14/542,495, filed Nov. 14, 2014 Final Office Action dated Aug. 31, 2016.
U.S. Appl. No. 14/542,495, filed Nov. 14, 2014 Non-Final Office Action dated May 10, 2016.
U.S. Appl. No. 14/542,495, filed Nov. 14, 2014 Notice of Allowance dated Nov. 15, 2016.
U.S. Appl. No. 14/675,236, filed Mar. 31, 2015 Non-Final Office Action dated Feb. 2, 2017.
U.S. Appl. No. 14/675,236, filed Mar. 31, 2015 Notice of Allowance dated May 16, 2017.
U.S. Appl. No. 14/799,547, filed Jul. 14, 2015 Non-Final Office Action dated Mar. 16, 2018.
U.S. Appl. No. 14/799,547, filed Jul. 14, 2015 Restriction Requirement dated Nov. 30, 2017.
U.S. Appl. No. 14/930,526, filed Nov. 2, 2015 Final Office Action dated Jun. 7, 2018.
U.S. Appl. No. 14/930,526, filed Nov. 2, 2015 Non-Final Office Action dated Feb. 23, 2016.
U.S. Appl. No. 14/930,526, filed Nov. 2, 2015 Notice of Allowance dated Oct. 2, 2018.
U.S. Appl. No. 16/384,481, filed Apr. 15, 2019 Non-Final Office Action dated Sep. 14, 2021.
PCT/US2004/005102 filed Feb. 19, 2004 Search Report dated Dec. 27, 2004.
PCT/US2004/005102 filed Sep. 19, 2004 Written Opinion dated Aug. 21, 2005.
PCT/US2008/078551 filed Oct. 2, 2008 International Preliminary Report on Patentability dated Apr. 20, 2010.
PCT/US2008/078551 filed Oct. 2, 2008 Search Report dated Mar. 13, 2009.
PCT/US2008/078551 filed Oct. 2, 2008 Written Opinion dated Mar. 13, 2009.
PCT/US2008/078560 filed Oct. 2, 2008 Preliminary Report on Patentability dated Aug. 26, 2010.
PCT/US2008/078560 filed Oct. 2, 2008 Search Report dated Mar. 16, 2009.
PCT/US2008/078560 filed Oct. 2, 2008 Written Opinion dated Mar. 16, 2009.
PCT/US2008/078566 filed Oct. 2, 2008 International Preliminary Report on Patentability dated Apr. 20, 2010.
PCT/US2008/078566 filed Oct. 2, 2008 Search Report dated Mar. 19, 2009.
PCT/US2008/078566 filed Oct. 2, 2008 Written Opinion dated Mar. 19, 2009.
PCT/US2008/078571 filed Oct. 2, 2008 Preliminary Report on Patentability dated Aug. 26, 2010.
PCT/US2008/078571 filed Oct. 2, 2008 Search Report dated Mar. 20, 2009.
PCT/US2008/078571 filed Oct. 2, 2008 Written Opinion dated Mar. 20, 2009.
PCT/US2008/080463 filed Oct. 20, 2008 Preliminary Report on Patentability dated Apr. 27, 2010.
PCT/US2008/080463 filed Oct. 20, 2008 Search Report dated Mar. 16, 2009.
PCT/US2008/080463 filed Oct. 20, 2008 Written Opinion dated Apr. 16, 2009.
PCT/US2008/082106 filed Oct. 31, 2008 International Preliminary Report on Patentability dated May 4, 2010.
PCT/US2008/082106 filed Oct. 31, 2008 Search Report dated Jan. 12, 2009.
PCT/US2008/082106 filed Oct. 31, 2008 Written Opinion dated Jan. 12, 2009.
PCT/US2014/066811 filed Nov. 21, 2014 International Search Report and Written Opinion dated Apr. 15, 2015.
Picture of Device believed to be partial sample of a product believed to have been sold in the United States with Polycath and/or Infuse-a-Cath Instructions for Use, 1 page, 2011.
Quinton® Catheter Products (1993).
Raaf Dual Lumen Right Atrial Catheters Brochure—Quinton Instrument Co., 6 pages, 1993.
Raaf, et al., Open Insertion of Right Atrial Catheters Through the Jugular Veins, Surgery, Gynecology & Obstetrics, 1993, vol. 177, pp. 295-298.
Rawn, et al., The Hemodialysis Access, Chapter 9, pp. 9.1-9.11, available at <<http://msl1.mit.edu/ESD10/kidneys/HndbkPDF/Chap09.pdf>>, last accessed Jun. 4, 2012.
Schwab, et al., Prospective Evaluation of a Dacron Cuffed Hemodialysis Catheter for Prolonged Use, American Journal of Kidney Diseases, 1988, vol. XI, No. 2, pp. 166-169.
Schwab, et al., Vascular Access: Case Oriented Discussions of Selected Critical Issues: Hemodialysis Catheters for Permanent Use, 1999.
Septum, Wikipedia, The Free Encyclopedia, hhtp://en.wikipedia.org/wiki/Septum (last visited Dec. 18, 2012) (defining “septum” as “a wall, dividing a cavity or structure into smaller ones”).
Shaffer, D., Catheter-Related Sepsis Complicating Long-Term Tunnelled Central Venous Dialysis Catheters: Management by Guidewire Exchange, American Journal of Kidney Diseases, 1995, vol. 25, No. 4, pp. 593-596.
Shaffer, D., Lessons From Vascular Access Procedures for Hemodialysis, Surgical Oncology Clinics of North America, 1995, vol. 4, No. 3, pp. 537-549.
Sioshansi, P., New Processes for Surface Treatment of Catheters, Artificial Organs, 1994, 18(4):266-271.
Swartz, et al., Successful Use of Cuffed Centrol Venous Hemodialysis Catheters Inserted Percutaneously, J. Am. Soc. Nephrol., 1994, 4:1719-1725.
Taber's Cyclopedic Medical Dictionary 1662 (16th ed. 1989) (defining “septum” as a “wall dividing two cavities”).
Tal, Michael G, Comparison of Recirculation Percentage of the Palindrome Catheter and Standard Hemodialysis Catheters in a Swine Model, J Vasc Interv Radiol, pp. 1237-1240, vol. 16, No. 9, 2005.
Tesio, et al., Double Catheterization of the Internal Jugular Vein for Hemodialysis: Indications, Techniques, and Clinical Results, Artificial Organs, 1994, vol. 18, No. 4, pp. 301-304.
The Groshong™ Peripherally Inserted Central Venous Catheter Brochure—Cath-tech®, 4 pages, 1988.
Transcript of Videotaped Deposition of Gregory Haas (Excerpt), Sep. 23, 2003, Thierry Pourchez and Bard Access Systems, Inc. v. Diatek, Inc. and Arrow International, Inc., Civil Action No. 03-CV-0972 (S.D.N.Y.).
Transcript of Videotaped Deposition of Thierry Pourchez, vol. 1, Oct. 16, 2003, Thierry Pourchez and Bard Access Systems, Inc. v. Diatek, Inc. and Arrow International, Inc., Civil Action No. 03-CV-0972 (S.D.N.Y.).
Transcript of Videotaped Deposition of Thierry Pourchez, vol. 2, Oct. 17, 2003, Thierry Pourchez and Bard Access Systems, Inc. v. Diatek, Inc. and Arrow International, Inc., Civil Action No. 03-CV-0972 (S.D.N.Y.).
Treiman, et al., Chronic Venous Access in Patients with Cancer, Cancer, 1993, vol. 72, No. 3, pp. 760-765.
Twardowski et al. “Side Holes at the Tip of Chronic Hemodialysis Catehters are Harmful,” The Journal of Vascular Access 2001; 2:8-16.
Twardowski et al., “Blood Recirculation in Intravenous Catheters for Hemodialysis” J. Am. Soc. Nephrol. 3:1978-81 (1993).
TYCO Healthcare, Mahurkar Dual Lumen Catheters, Informational Brochure, 2 pages, 2004.
TYCO Healthcare, Mahurkar QPlus High Flow Acute Care Catheter, Informational Brochure, 2 pages, 2004.
TYCO Healthcare, Tal Palindrome™ Dual Lumen Catheters Order Information, Features and Benefits, Frequently Asked Questions, printed from http://www.kendallvasculartherapy.com/VascularTherapy, 6 pages, on Mar. 1, 2007.
Uldall, P., Subclavian Cannulation Is No Longer Necessary or Justified in Patients with End-Stage Renal Failure, Seminars in Dialysis, 1994, vol. 7, No. 3, pp. 161-164.
U.S. Appl. No. 10/371,774, filed Feb. 21, 2003 Final Office Action dated Jan. 19, 2007.
U.S. Appl. No. 10/371,774, filed Feb. 21, 2003 Final Office Action dated Mar. 7, 2007.
U.S. Appl. No. 10/371,774, filed Feb. 21, 2003 Non-Final Office Action dated Jul. 17, 2006.
U.S. Appl. No. 10/371,774, filed Feb. 21, 2003 Notice of Allowance dated Jun. 1, 2007.
U.S. Appl. No. 10/445,731, filed May 27, 2003 Non-Final Office Action dated Apr. 13, 2007.
U.S. Appl. No. 10/445,731, filed May 27, 2003 Non-Final Office Action dated Dec. 12, 2008.
U.S. Appl. No. 10/445,731, filed May 27, 2003 Non-Final Office Action dated May 30, 2008.
U.S. Appl. No. 10/842,586, filed May 10, 2004 Advisory Action dated Oct. 9, 2008.
U.S. Appl. No. 10/842,586, filed May 10, 2004 Final Office Action dated Jul. 29, 2008.
U.S. Appl. No. 10/842,586, filed May 10, 2004 Final Office Action dated May 25, 2010.
U.S. Appl. No. 10/842,586, filed May 10, 2004 Non-Final Office Action dated Jan. 7, 2008.
U.S. Appl. No. 10/842,586, filed May 10, 2004 Non-Final Office Action dated Jun. 16, 2009.
U.S. Appl. No. 10/842,586, filed May 10, 2004 Non-Final Office Action dated Nov. 13, 2008.
U.S. Appl. No. 10/842,586, filed May 10, 2004 Non-Final Office Action dated Nov. 23, 2009.
U.S. Appl. No. 10/874,298, filed Jun. 9, 2004 Advisory Action dated Feb. 19, 2009.
U.S. Appl. No. 10/874,298, filed Jun. 9, 2004 Final Office Action dated Jul. 15, 2008.
U.S. Appl. No. 10/874,298, filed Jun. 9, 2004 Final Office Action dated Jul. 7, 2010.
U.S. Appl. No. 10/874,298, filed Jun. 9, 2004 Final Office Action dated Mar. 18, 2014.
U.S. Appl. No. 10/874,298, filed Jun. 9, 2004 Non-Final Office Action dated Aug. 1, 2013.
U.S. Appl. No. 10/874,298, filed Jun. 9, 2004 Non-Final Office Action dated Aug. 18, 2011.
U.S. Appl. No. 10/874,298, filed Jun. 9, 2004 Non-Final Office Action dated Dec. 30, 2009.
U.S. Appl. No. 10/874,298, filed Jun. 9, 2004 Non-Final Office Action dated Feb. 2, 2011.
U.S. Appl. No. 10/874,298, filed Jun. 9, 2004 Non-Final Office Action dated Jul. 23, 2009.
U.S. Appl. No. 10/874,298, filed Jun. 9, 2004 Non-Final Office Action dated Jul. 9, 2014.
U.S. Appl. No. 10/874,298, filed Jun. 9, 2004 Non-Final Office Action dated May 23, 2006.
U.S. Appl. No. 10/874,298, filed Jun. 9, 2004 Non-Final Office Action dated May 24, 2007.
U.S. Appl. No. 11/859,106, filed Sep. 21, 2007 Final Office Action dated Sep. 1, 2009.
U.S. Appl. No. 11/859,106, filed Sep. 21, 2007 Non-Final Office Action dated Feb. 5, 2009.
U.S. Appl. No. 11/859,106, filed Sep. 21, 2007 Non-Final Office Action dated Mar. 30, 2011.
U.S. Appl. No. 11/859,106, filed Sep. 21, 2007 Non-Final Office Action dated Jun. 25, 2008.
U.S. Appl. No. 11/874,447, filed Oct. 18, 2007 Decision on Appeal dated Dec. 26, 2012.
U.S. Appl. No. 11/874,447, filed Oct. 18, 2007 Examiner's Answer dated Apr. 28, 2010.
U.S. Appl. No. 11/874,447, filed Oct. 18, 2007 Final Office Action dated Jul. 22, 2009.
U.S. Appl. No. 11/874,447, filed Oct. 18, 2007 Non-Final Office Action dated Jan. 6, 2009.
U.S. Appl. No. 11/874,447, filed Oct. 18, 2007 Non-Final Office Action dated Jul. 12, 2013.
U.S. Appl. No. 11/874,447, filed Oct. 18, 2007 Non-Final Office Action dated Jul. 9, 2008.
U.S. Appl. No. 11/874,447, filed Oct. 18, 2007 Notice of Allowance dated Apr. 18, 2014.
U.S. Appl. No. 12/048,871, filed Mar. 14, 2008 Decision on Appeal dated Feb. 2, 2015.
U.S. Appl. No. 12/048,871, filed Mar. 14, 2008 Examiner's Answer dated Feb. 9, 2012.
U.S. Appl. No. 12/048,871, filed Mar. 14, 2008 Final Office Action dated Jan. 20, 2011.
U.S. Appl. No. 12/048,871, filed Mar. 14, 2008 Final Office Action dated Jan. 4, 2016.
U.S. Appl. No. 12/048,871, filed Mar. 14, 2008 Non-Final Office Action dated Aug. 31, 2016.
U.S. Appl. No. 12/048,871, filed Mar. 14, 2008 Non-Final Office Action dated Jan. 7, 2010.
U.S. Appl. No. 12/048,871, filed Mar. 14, 2008 Non-Final Office Action dated Jul. 16, 2015.
U.S. Appl. No. 12/048,871, filed Mar. 14, 2008 Non-Final Office Action dated Jul. 7, 2010.
U.S. Appl. No. 12/048,871, filed Mar. 14, 2008 Non-Final Office Action dated May 12, 2009.
U.S. Appl. No. 12/048,871, filed Mar. 14, 2008 Notice of Allowance dated Feb. 10, 2017.
U.S. Appl. No. 12/244,514, filed Oct. 2, 2008 Non-Final Office Action dated Jan. 17, 2012.
U.S. Appl. No. 12/244,559, filed Oct. 2, 2008 Decision on Appeal dated Aug. 31, 2015.
U.S. Appl. No. 12/244,559, filed Oct. 2, 2008 Examiner's Answer dated Mar. 27, 2013.
U.S. Appl. No. 12/244,559, filed Oct. 2, 2009 Final Office Action dated Jul. 3, 2012.
U.S. Appl. No. 12/244,559, filed Oct. 2, 2009 Non-Final Office Action dated Mar. 14, 2012.
U.S. Appl. No. 16/384,481, filed Apr. 15, 2019 Notice of Allowance dated Jan. 18, 2022.
Herts, B. R. et al., “Power Injection of Contrast Media Using Central Venous Catheters: Feasibility, Safety, and Efficacy.” AJR Am J Roentgenol. Feb. 2001;176(2):447-53. (Feb. 2001).
Related Publications (1)
Number Date Country
20200129729 A1 Apr 2020 US
Provisional Applications (2)
Number Date Country
61907344 Nov 2013 US
60984661 Nov 2007 US
Divisions (2)
Number Date Country
Parent 15442608 Feb 2017 US
Child 16725996 US
Parent 14549941 Nov 2014 US
Child 15442608 US
Continuations (1)
Number Date Country
Parent 12262820 Oct 2008 US
Child 13329156 US
Continuation in Parts (1)
Number Date Country
Parent 13329156 Dec 2011 US
Child 14549941 US